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SUMMARY 
The association between cancer and venous thromboembolism (VTE) was described already 
in the 19th century and cancer has later been acknowledged as one of the most important 
risk factors for VTE. Population-based studies on the subject with information about 
confounders and validated endpoints are lacking. The first aim of this thesis was to estimate 
the frequency of VTE among cancer patients in a population-based cohort study and assess 
the risk among cancer patients compared to a cancer-free reference population.  Secondly, 
we wanted to investigate whether the level of leukocytes and platelets at inclusion 
influenced the future risk of VTE in cancer patients and in those who remained cancer-free.  
 The fourth survey of the Tromsø study (Tromsø IV) was applied in all four papers of 
this thesis. The Tromsø Study is a prospective study of adult inhabitants of Tromsø. In 
Tromsø IV (1994-95), information from more than 27 000 subjects were collected by physical 
examination, self-administrated questionnaires and blood tests, and VTE events were 
registered throughout 2010. Information about cancer was provided by the Cancer Registry 
of Norway. In paper II, the Tromsø IV cohort was merged with two additional Scandinavian 
cohorts (i.e. HUNTII and DCH) and 137 000 subjects were included in the study.  
 VTE occurred among 3-5 % of the cancer patients. Malignancy accounted for 20-25 % 
of the VTE events in the population, and the proportion was highest among middle-aged 
where cancer explained almost 30 % of the events. Patients with malignancy exhibited an 
overall 5-fold increased risk of VTE. The risk was highest during the initial 6 months after 
diagnosis (i.e. 17-fold increased) and declined thereafter. Patients with certain cancers, such 
as pancreatic-, lung- and brain cancers, had a particularly high risk of VTE. However, most 
cancers exhibited a high risk during the initial 6 months after diagnosis with incidence rates 
ranging from 30-90 cases per 1000 person-years for all sites, except for breast- and prostate 
cancers which had substantially lower risks.  Despite the strong association between high 
age and VTE in the general population, the risk of VTE was similar across age-categories 
within the first year after a cancer diagnosis. 
 We found that WBC- and platelet count were associated with VTE in cancer patients. 
Baseline leukocyte- or platelet count above the 80th percentile provided doubled risk of VTE 
compared to the 40th percentile, and the combined effect of the parameters was synergistic. 
The association was confined to subjects diagnosed with cancer, and the results suggest that 
platelet- and white blood cell counts have impact on the risk of cancer-related VTE.  
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SAMMENDRAG 
Sammenhengen mellom kreft og venøs blodpropp (i.e. VTE) ble beskrevet allerede på 1800-
tallet, og i dag er kreft en av de viktigste risikofaktorene for VTE vi kjenner til. Store 
befolkningsstudier med informasjon om tilleggsfaktorer og validerte diagnoser har manglet i 
kunnskapsbildet. Vi ønsket å undersøke forekomsten av kreft-relatert VTE i en stor, 
prospektiv kohort studie, og estimere den relative risikoen for VTE blant kreftpasienter 
sammenliknet med en kreftfri populasjon. Videre ville vi se om antall hvite blodceller og 
blodplater hadde innvirkning på VTE-risikoen hos de som utviklet kreft og hos de som forble 
kreftfri gjennom studieperioden. 
 Data fra den fjerde Tromsøundersøkelsen gjennomført i 1994-95 (Tromsø IV) er brukt 
i alle fire artiklene i avhandlingen. Alle innbyggere i Tromsø kommune som var fylt 25 år ble 
invitert, og 27 000 personer deltok (77% av de inviterte). Informasjon om deltakerne ble 
innhentet ved hjelp av klinisk undersøkelse, spørreskjemaer og blodprøver, og 
kreftdiagnoser ble registrert ved kobling til Kreftregisteret. VTE hendelser blant deltakerne 
ble registrert fra inklusjon til 2010. Artikkel II er basert på en sammenslått populasjon 
bestående av Tromsø IV og to andre Skandinaviske befolkningsstudier (HUNTII og DCH), og 
137 000 deltakere inngikk i den studien.  
VTE ble diagnostisert hos 3-5% av kreftpasientene gjennom oppfølgingstiden. Kreft 
kunne forklare hele 20-25% av VTE-tilfellene i befolkningen, og andelen var høyest blant 
middelaldrende der nærmere 30 % av tilfellene var forklart av kreft. Sammenliknet med 
kreftfrie deltakere hadde de som utviklet kreft 5 ganger høyere risiko for VTE. Risikoen var 
høyest i de første 6 månedene etter diagnosen og falt deretter. Enkelte krefttyper som 
bukspyttkjertelkreft, lungekreft og hjernesvulster var assosiert med høyest risiko, men alle 
krefttyper ga høy risiko i den første tiden etter diagnosen. Høy alder, som vanligvis er en 
sterk disponerende faktor for VTE, var bare svakt assosiert med VTE i det første året etter en 
kreftdiagnose. 
 Konsentrasjonen av hvite blodceller og blodplater i blodet målt før kreftutvikling 
påvirket VTE-risikoen hos de som utviklet kreft. Begge parameterne ga hver for seg en 
dobling i risiko når 80-persentilen ble sammenliknet med 40-persentilen, og den kombinerte 
effekten av høye konsentrasjoner av hvite blodceller og blodplater var synergistisk. 
Resultatene tyder på at basalnivået at hvite blodceller og blodplater bidrar til utvikling av 
blodpropp hos kreftpasienter.   
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1       INTRODUCTION 
Venous thromboembolism (VTE) is a collective term for deep vein thrombosis (DVT) 
and pulmonary embolism (PE). DVT is development of a blood clot in the deep veins, 
primarily of the lower extremities, that prohibits normal venous blood flow back towards the 
heart. The condition leads to pain, redness and swelling of the affected extremity. 
Pulmonary embolism is traditionally understood as a complication of DVT where a part of 
the clot, an embolus, breaks free from its origin and is carried with the blood-stream to the 
arterial circulation of the lungs. Where the vessel narrows, the clot is fixed and may obstruct 
the blood flow of the respective pulmonary artery. However, the origin of the pulmonary 
emboli remains undetected in up to 50 % of PE patients (1, 2). This may be due to 
evaporation or dislodging of the entire DVT, but novel origins such as cardiac thrombi and de 
novo thrombus formation in the lung arteries may also be possible. Classical signs and 
symptoms of pulmonary embolism are dyspnea, tachypnea and pleuritic chest pain. 
Depending on the size of the embolus, the clinical course of a pulmonary embolism ranges 
from asymptomatic to fatal circulatory collapse (3, 4). Patients diagnosed with VTE are 
treated with anticoagulants, and the standard treatment consists of concomitant low 
molecular weight heparin (LMWH) and a vitamin K antagonist (VKA) in the initial phase, 
followed by VKA monotherapy in the long-term treatment (5). Direct oral anticoagulants 
(DOACs) are now being implemented in the standard treatment of VTE patients.  
The association between cancer and venous thrombosis was described already in the 
19th century, and has been termed the Trousseau syndrome after one of the early 
discoverers (6, 7). The link between cancer and VTE has later been convincingly 
demonstrated in a number of publications, and today cancer is acknowledged as one of the 
most important risk factors for venous thromboembolism in the population. However, the 
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pathophysiology of these thrombi is not fully understood, and large variations in risk have 
been demonstrated with regard to cancer- and patient-related characteristics.  
 In the past decades attention has been addressed towards identification of patients 
at risk for appropriate use of prophylaxis and improved antithrombotic treatment in patients 
with cancer.  The CLOT Trial from 2003 detected lower rates of recurrent VTE in cancer 
patients treated with LMWH compared to VKA, and is the basis for the current 
recommendation of LMWH monotherapy in cancer-associated VTE (8, 9). The DOACs have 
not been tested in appropriate trials of cancer patients or compared to long-term treatment 




1.1.1 Venous thromboembolism in the general population 
Venous thromboembolism occurs in 1-2 per 1000 adults in Western countries 
annually, and is the third most common cardiovascular disease after myocardial infarction 
and stroke (12). The clinical presentation as deep vein thrombosis is more common than 
pulmonary embolism, and occurs approximately at a 2:1 ratio (3, 13, 14). The two conditions 
are often present at the same time. Silent pulmonary embolisms have been observed in 50-
80 % of the patients with acute DVT (15), and compression ultrasonography or venography 
in patients with pulmonary embolism revealed DVT in about 50 % of the patients (1, 2, 16).  
A VTE event is classified as provoked or unprovoked (idiopathic), based on the 
presence or absence of provoking factors. Provoking factors are transient conditions or 
situations which are associated with VTE and include hospitalization, acute medical illness, 
malignancy, surgery, trauma, plaster-cast and long-haul travel. The concept may also 
  
  13 
 
comprise certain lasting conditions such as paralysis and wheel-chair use. In general, the 
presence of provoking factors is associated with lower recurrence rates (17) and justifies a 
shortened long-term treatment (5). Population-based studies estimate that 50-60 % of the 
VTE events are associated with provoking factors (13, 14, 18, 19).  
VTE is a disease with serious short-and long-term consequences. One-month case-
fatality rates of 10-15 % for PE and of 5-10 % for DVT have been reported (3, 13, 19). 
Additionally, sudden deaths caused by unsuspected PE are often misinterpreted as 
myocardial infarction (20), and was the single diagnosis most often missed by clinicians (21). 
However, it has also been emphasized that only a low proportion of deaths that follow PE 
are attributable to the PE itself (22-24). Major bleeding during treatment, defined as fatal 
bleeding, bleed into critical sites, fall of ≥ 2 g/dl hemoglobin or requirement for transfusion 
of two or more units of blood, have been reported in 1-2 % of the patients in recent clinical 
trials (25). Despite appropriate therapy, recurrence is common and occurs in 10-30 % of 
patients with unprovoked VTE within five years (26-28), and tends to have the same location 
(PE/DVT) as the initial event (27, 29, 30). Recurrence more often follows DVT than PE (27, 
29), and is more common in men than women (26, 31). Post-thrombotic syndrome, 
characterized by chronic pain, swelling, stasis dermatitis and in severe cases leg ulcers and 
intractable edema, develops in 20-50 % of the DVT-patients (32, 33).  
  
1.1.2 Venous thromboembolism in cancer patients 
Malignant diseases are present in 15-25 % of all venous thrombotic events in a 
general population, and recent literature suggests that cancer is associated with an overall 4-
7 fold increased risk of venous thrombosis compared to subjects without cancer (34-36). 
However, the risk-estimates for cancer-associated VTE rely on many cancer- and patient 
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characteristics, as well as methodological aspects such as duration of follow-up, patient 
selection and the identification of the VTE events (Table 1).  Clinical trials of 
thromboprophylaxis in hospitalized medical patients with cancer and in oncology patients 
attending out-patient clinics have reported rates of VTE of 4-20 % (37) and 3-4 % (38, 39) in 
the respective placebo groups. Corresponding observational studies have observed 
cumulative risks of 2-7 % (40-43) (Table 1).  
Although the above-mentioned studies provide relevant risk-estimates during high-
risk settings, population-based studies and general cancer cohorts are important in terms of 
estimating the disease burden at population level. In epidemiological studies where the 
cancer diagnoses are obtained from cancer-registries and encompass all sites and stages, the 
rates of VTE are fairly low, and reported rates range from 0.8 % per year  to 1.2 % within the 
first 6 months (34, 44, 45). In these studies, the observation-time is not confined to specific 
exposures such as active treatment, hospitalizations or progression of the disease, and show 
a clear trend of decreased risk from the date of the cancer diagnosis throughout follow-up. 
Blom and co-workers investigated site- and stage-specific incidence rates of VTE and 
assessed the impact of treatment modalities in a population based cancer cohort (44). 
Incident cancers between 1986 and 2002 were obtained from the Dutch cancer registry, and 
VTE events were collected from two outpatient anticoagulation clinics. The 6-month 
cumulative risk varied across cancer sites and ranged from 1-6 %. A limitation of the study 
was the detection of VTE diagnosis at outpatient clinics, which did not capture severe cases 
with poor prognosis that were managed in-hospital only or patients who died before 
registration at the anticoagulation clinics. A similar study by Chew and colleagues obtained 
cancer-diagnoses from the Californian Cancer Registry between 1993 and 1995 and reported 
VTE rates by linkage to the state registry of discharge diagnoses (45). The highest rate was 
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observed in patients with remote pancreatic cancer where 5.4 % developed VTE within 2 
years, and a clear trend from localized to advanced disease was observed in each cancer site.  
Concurrent with the beginning of this project, Cronin-Fenton and colleagues 
published the first prospective study to investigate the risk of VTE in patients with cancer 
compared to the general population (34). This Danish registry-based study of 57 600 patients 
with cancer and 287 500 controls reported that risk of VTE in cancer-patients was increased 
almost 5-fold (HR 4.7), and found an incidence rate of 1.4 % in the first year after a diagnosis 
of cancer. However, the study was confined to hospitalized cases. This might be problematic 
because the risk estimates (i) might have been influenced by a differential bias in the 
outcome assessment (i.e. different hospitalization rate for VTE-patients with and without 
cancer) and (ii) did not capture the total VTE burden in the population. Furthermore, similar 
to the study by Chew and colleagues, the VTE events were retrieved from a national 
diagnosis registry without validation. The estimated positive predictive value of a VTE-
diagnosis in a sub-cohort was only 75 % (46). A study of discharge diagnosis from France 
found that the sensitivity of ICD-10 codes was better for PE than DVT, and that VTEs that 
developed during hospitalization or after surgery often were missed (47).  
  
  




Authors, year Study design 









Levitan et al, 1999 
(48) 
(1988-1990) 
1 200 000 cancer 
patients  
- 0.6 %  
Blom et al, 2005 (35) 
Case-control study 
(MEGA) 
3220 VTE patients 6.7 (OR) - 
Blom et al, 2006 (44) 
Registry-based cohort 
study 
66 329 cancer patients - 
12 per 1000 (6-months 
cumulative risk) 




235 149 cancer patients - 
1.6 % (2-year cumulative 
risk) 
Cronin-Fenton et al, 
2010 (34)* 
Population based cohort 
study 
(registry based) 
57 591 cancer patients 
287 476 controls 
4.7 (HR) 1.4 % (1-year incidence) 
Walker et al, 2013 
(49)* 
Population based cohort 
study (registry based) 
83 203 cancer patients 
577 207 controls 
4.7 (HR) 












6.5 % (cumulative risk 
during all hospitalizations) 
Stein et al,2006 (41) 
Nationwide registry-
based cohort (1979-1999) 
40 787 000 patients 
hospitalized with cancer 
2.0 (OR) 2 %  
Outpatients 
with cancer 
Khorana et al, 2008 
(42) 
Prospective cohort study 
(ANC Study Group 
Registry) (2002-2005) 
4 066 ambulatory  cancer 
patients  
- 
2 % (cumulative risk after a 
median of 2.5 months) 
Ay et al, 2010 (43) 
Prospective cohort 
study(CATS) (2003-2008) 
819 ambulatory  
cancer patients 
- 
7.4 % (cumulative risk after 
a median of 2 years) 
Pharmaceutical 
trials 
Agnelli et al, 2009 
(38) 
Trial of VTE prophylaxis 





3.2 % (cumulative risk 
within 150 days in the 
placebo group) 
Agnelli et al, 2012 
(39) 
Trial of VTE prophylaxis 





3.4 % (cumulative risk after 
a median of 3.5 months in 
the placebo group) 
Samama et al, 1999 
(50) 
Trial of VTE prophylaxis 
in hospitalized medical 
patients (Medenox) 
41 enoxaparin (cancer) 
31 placebo (cancer) 
- 
10 % VTE with prophylaxis 
20 % VTE with placebo 
Leizorovicz, 2004 
(51) 
Trial of VTE prophylaxis 
in hospitalized medical 
patients (Prevent) 
72 dalteparin (cancer) 
65 placebo (cancer) 
- 
3 % VTE with prophylaxis 
8 % VTE with placebo 
Cohen, 2006 (52) 
Trial of VTE prophylaxis 
in hospitalized medical 
patients (Artemis) 
51 fondaparinux (cancer) 
47 placebo (cancer) 
- 
17 % VTE with prophylaxis 
4 % VTE with placebo 
Table 1. Risk of VTE in patients with cancer categorized by study population.  
* Published during the work of this thesis 
 
  
  17 
 
The relative importance of different exposures may be expressed as attributable 
proportions. A few studies have reported attributable risk of cancer in the etiology of VTE 
(53, 54). The most reliable estimates suggested that cancer was responsible for 15 % of the 
VTE events in young subjects, and 35 % among the elderly (54). However, the relative risks 
that were applied in the calculations were not age-specific, and the estimates are biased if 
the relative risk varies across age-groups. No study has previously assessed the attributable 
risk of cancer based on incidence rates of VTE among cancer and non-cancer subjects.  
VTE is a serious disease in cancer patients. Fatal PE after an initial VTE event is higher 
among cancer patients compared to cancer-free patients (55, 56), and bleeding 
complications during anticoagulant treatment are more common than in cancer-free 
subjects. In the RIETE registry, major bleeding was registered among 4 % during the first 
three months of treatment (57) whereas the 1-year cumulative rate has been reported to be 
10-15 % (58-60). Cancer has also been associated with several-fold increased risk of 
recurrent VTE (19, 48)  which was detected among approximately 15-20 % within the first 
year (58-60). Other adverse effects of VTE in this patient group are interruption of 
chemotherapy and more frequent and prolonged hospitalizations (59, 61, 62). The frequency 
of post-thrombotic syndrome among patients who have suffered from cancer-associated 
VTE is not known, but is presumably high among survivors due to the high recurrence rate.  
Sørensen and co-workers were the first to demonstrate that cancer patients who 
developed VTE had a poor prognosis compared to cancer patients without VTE (63). The 
study was based on three linked databases; the Danish National Registry of Patients, the 
Danish Cancer Registry and the Danish Mortality Files. They found that the patients with  
cancer and VTE had a two-fold increased risk of death and that the prevalence of distant 
metastasis was higher among the VTE-patients. However, the cancer stage was not 
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considered in the mortality estimates, and the study was therefore not able to discriminate 
between more aggressive cancers or the thrombotic event as the cause of increased 
mortality. Several studies have confirmed the findings of Sørensen et al. Chew and 
colleagues found that the mortality of cancer-related VTE remained increased after 
adjustment for age and cancer stage (45). A study of colorectal-cancer patients reported 
increased mortality after VTE in patients with localized and regional disease, but not among 
patients with distant metastasis (64). The authors suggested that the increased mortality 
among those with non-advanced cancers and VTE was due to more aggressive cancer in the 
VTE patients not captured by stage. Recent mortality estimates from the Tromsø cohort 
found that VTE patients without cancer had a crude death-rate of 5.1 per 100 person-years, 
as compared to 12.7 per 100 person-years for cancer only and 55 per 100 person-years for 
those with cancer-related VTE (65). 
In a frequently cited paper from 2007 Khorana et al investigated the causes of death 
among outpatients who received chemotherapy (66). Among 4466 patients enrolled in the 
ANC (Awareness of Neutropenia in Chemotherapy) Study Group Registry, 141 deaths (3.1%) 
were registered during a median follow-up of 75 days. 71% of the deaths were assumed to 
be a result of cancer progression. Thromboembolic events, including arterial and venous 
thrombosis, were registered as cause of death in 9% of the cases, and venous thrombosis 
accounted for 3.5 %. Lethal infections were equally common as thrombosis altogether and 
were responsible for 9% of the cases. In this study, the causes of death were not verified by 
autopsy, but retrieved directly from the death certificate. As stated by the authors, autopsy 
studies have revealed higher rates of pulmonary embolism among cancer patients than the 
rates reported for symptomatic VTE.  A Norwegian study of autopsies performed between 
1960 and 1984 reported pulmonary embolism in 10.5% of the 6200 subjects with a 
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registered malignancy, and in 8.4 % of the 21 500 subjects without malignancy (67). 
Similarly, another autopsy study of subjects who died in hospital reported that fatal PE had 
occurred in 14 % of the patients with cancer and in 8 % among the cancer free subjects, and 
further stated that 60% of the patients who died from PE had localized or limited metastatic 
cancers without poor prognosis (68). A Swedish study from 1970-1982 found even higher 
rates of PE in cancer patients, where 23 % of the patients had PE, of which more than 40 % 
were considered fatal (69). The highest rate of PE was observed in patients with pancreatic 
cancer where PE was confirmed in more than 40 % of the patients. Thus, the finding that 
3.5% of deaths were due to VTE in the ANC Study Group Registry was probably too low. 
Updated autopsy studies are needed to estimate the true impact of VTE on the mortality 
among cancer- and non-cancer patients.   
Altogether, cancer associated thrombosis leads to substantial resource claims and 
health care costs (59). In a retrospective study, VTE and VTE-related complications occupied 
6 % of the bed-capacity at an oncology department (70), and adjusted measures have 
suggested that the average economic burden attributable to VTE in patients with cancer was 
close to 10 000 USD per patient within the first year after the event (61).  
An increasing incidence of VTE among cancer patients has been noted in several 
studies (40, 41). From 1979 to 1999, Stein and colleagues observed an increase in the VTE-
rate from 1.5 % to 3.5 % among hospitalized patients with cancer, whereas no such trend 
was observed in patients without a cancer diagnosis (41). The increase was most prominent 
in the 1990s, and was primarily caused by an increased frequency of DVT. Khorana and co-
workers reported a 36 % increased risk of VTE among neutropenic cancer patients in the 
period 1995 until 2002 (40). Improved survival among cancer patients, more aggressive 
cancer treatment as well as increased awareness of cancer-associated VTE have been 
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suggested as likely explanations. The notion that the PE rate has remained constant 
undermines that incidentally detected VTE is the primary cause.  
However, due to improved imaging techniques, incidental VTE detected during the 
diagnostics work-up or staging in cancer patients is common, and has been reported in 4 % 
of cancer patients who undergo computed tomography of the chest for reasons other than 
suspected PE (71). Similar rates of recurrence and mortality has been noted in patients with 
symptomatic and asymptomatic cancer-related VTE (60), and guidelines suggest that 
incidental PE should be managed like symptomatic events (5, 72).   
The risk of VTE is highly dependent on the cancer site and rates of VTE in various 
cancers have been reported in a number of studies (73). Due to methodological variations 
between studies, the comparison of VTE risk in different cancers should probably be based 
on studies where several sites are included and cancer sites can be compared directly. Chew 
and colleagues found that advanced cancers of pancreas, uterus and stomach were 
associated with the highest risk, and that pancreatic cancer provided a clearly higher risk 
among the localized cancers (45). High risk in pancreatic cancer has also been noted by 
others, along with brain and ovarian cancer (44, 48). Prostate and breast cancers have 
generally been associated with a low risk of VTE (73).  
 
1.2 Pathophysiology  
1.2.1 General pathophysiology of venous thromboembolism  
Hemostasis is essential in the physiological management of vascular injury, but may 
cause severe disease when it propagates within the vasculature. This process is termed 
thrombosis and is typically described by two distinct, but interlinked pathways.  
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Blood platelets, which are derived from megakaryocytes in the bone marrow (74) and 
are the smallest among the circulating cells, are responsible for the initial seal at the site of 
injury (75). Several receptors and ligands influence the platelet function. The platelet 
glycoprotein (GP) Ibα-receptor adhere platelets to the subendothelial tissue by binding to 
von Willebrand Factor (vWF) (76, 77). Fibrinogen, vWF and other ligands enable platelet 
aggregation and activation by binding to the receptor GP IIb/IIIa. Platelets are activated by 
addenosine diphosphate (ADP), collagen and thrombin. Activated platelets release a number 
of substances that further enhance platelet activation and recruitment, including ADP and 
thromboxane A2 (75). Aggregates of platelets cover the disrupted endothelium and form the 
primary platelet plug. Upon activation, platelets also undergo a conformational change 
which increases their surface area and adhesive properties. “Flip-flop” reactions within the 
platelet membrane translocate negatively charged phospholipids, such as 
phosphatidylserine (PS), to the outer leaf of the membrane (78). In the mid-nineties, 
Hoffmann and co-workers proposed a cell-based coagulation model, suggesting that the PS-
rich surface facilitates assembly of coagulation factors and provides a catalytic surface for 
several steps of coagulation (79).  
The coagulation system is a series of proteins that are activated in a cascade fashion 
that results in fibrin deposition (80). Subendothelial tissue exposed by injury express tissue 
factor (TF), a transmembrane protein recognized as the main trigger of coagulation in vivo 
(81). In complex with factor (F) VIIa, TF activates small amounts of FIX and FX (the extrinsic 
pathway of coagulation) (80). Activated FX (FXa) and its associated co-factor (FVa), also 
termed the prothrombinase complex, converts prothrombin (FII) to thrombin (IIa), and 
ultimately leads to fibrin deposition through a feed-forward mechanism (78, 80, 82). 
However, unlike arterial thrombosis where plaque rupture leads to exposure of 
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subendothelial ligands, venous thrombi are usually surrounded by intact endothelium (83, 
84). Extensive mechanistic research has aimed to identify the triggers of hemostasis in 
venous thrombosis. 
Today it is widely accepted that venous thrombi develop in the valvular sinuses of the 
venous valves (85, 86). In this particular area of the veins the blood tends to linger and is 
susceptible to desaturation. As the innermost layer of the vessel wall is supplied from the 
vessel lumen, low oxygen tension causes endothelial hypoxia that in turn induces a number 
of proinflammatory and procoagulant processes in endothelial cells as well as in circulating 
leukocytes and platelets (Figure 1). Down-regulation of anticoagulant proteins such as 
thrombomodulin and the endothelial protein C receptor (EPCR) reduce the anticoagulant 
activity, and increased expression of membrane-bound P-selectin and vWF recruits 
leukocytes and platelets to the hypoxic endothelium. Importantly, activated leukocytes and 
platelets bud off small phosphatidylserine-rich membrane vesicles (0.1-1 µm) known as 
microparticles (MPs) (87). MPs, and especially those derived from monocytes (88), may 
express TF (89). It has been suggested that TF-bearing (+) MPs are key triggers of venous 
thrombosis (90). However, the results are inconsistent (91-95) and the majority of studies 
are retrospective and susceptible to reversed causation (96). Thus, the role of MPs in non-
cancer VTE remains to be established.  
Leukocytes may further enhance thrombosis through surface expression of TF, 
recruitment of platelets and release of neutrophil extracellular traps (NETs). NETs were first 
described in 2004, and are webs of DNA containing histones and antibacterial proteins (97). 
NETs have previously been recognized as a part of the innate immune response towards 
bacterial infections, and have only recently been proposed as an important feature of 
neutrophil-driven coagulation (98, 99). 
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Figure 1. The pathophysiology of venous thromboembolism: blood is caught in a secondary vortex of 
the valve pockets and becomes desaturated. Hypoxia promotes proinflammatory and prothrombotic 
responses in endothelial cells, leukocytes and platelets (Plt). Endothelial P-selectin expression leads 
to docking of leukocytes to the endothelium. Activated platelets and leukocytes bud off procoagulant 
microparticles (MP). The MPs are procoagulant due to surface phosphatidylserine and in some cases 




1.2.2  Pathophysiology of cancer-related venous thromboembolism  
Markers of ongoing coagulation such as D-dimer, thrombin-antithrombin complexes 
and pro-thrombin fragment 1+2 are elevated in patients with cancer compared to healthy 
controls (100-102), and a number of mechanisms for cancer-induced hypercoagulability have 
been proposed. The malignant environment may induce intrinsic changes in the hemostatic 
system, and veins can be compressed by solid tumors leading to stasis or the endothelium 
may be damaged by invasive growth in the vessel wall. In addition, patients with cancer are 
subjected to a number of VTE risk factors during the course of a malignant disease, such as 
major surgery, chemotherapy, hospitalization, infections and bed-rest.   
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A cysteine proteinase termed cancer procoagulant was isolated from animal 
carcinoma cells already in 1985 (103). The molecule was able to activate FX directly and has 
been emphasized as an important contributor to activation of coagulation in cancer (102). 
Cancer-induced deficiency of the vWF cleavage protein ADAMST-13, causing unusually large 
von Willebrand multimeres has also been described (104).  Additionally, elevation in 
coagulation factors due to decreased hepatic clearance (100) and pro-coagulant 
endothelium caused by tumor derived cytokines as well as regulation of the fibrinolytic 
system (105) may be significant mediators of the pro-thrombotic state in cancer patients.  
Recent publications emphasize the role of tumor derived microparticles in cancer-
associated VTE (106, 107). Epithelial-derived malignant tissues often express TF (108-110), 
and together with monocytes, cancer cells are an important source of TF+MPs in the 
circulation (78, 106). TF-MP activity has been associated with more advanced cancer stage, 
higher tumor grade and decreased survival in patients with pancreatic cancers (111).  
Finally, leukocytosis and thrombocytosis are common findings in patients with cancer 
and have been associated with increased risk of cancer-associated VTE (112-115). However, 
elevated levels of these blood cells are considered as epiphenomenon of an inflammatory 
state and are associated with advanced malignant disease. Epidemiological studies may 
therefore be confounded by the presence of other pro-thrombotic conditions, and a 
potential role of high leukocyte or platelet count is difficult to evaluate. It is therefore not 
known whether high levels of cells per se contribute the procoagulant state in cancer 
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1.3 Risk factors 
1.3.1 Non-cancer related risk factors 
During the past decades, epidemiological studies have identified a number of risk 
factors for venous thrombosis. The three major causes of thrombosis postulated by Rudolph 
Virchow in the mid-1800s still apply, and suggest that thrombosis results from altered blood 
flow, hypercoagulability or vessel wall injury. In the modern literature, these causes are 
usually categorized as acquired or inherited risk factors.  
Acquired risk factors for VTE include high age, obesity, tall stature, immobility, 
medical illnesses, surgery, trauma, pregnancy, puerperium and female hormones, as well as 
cancer and cancer-associated factors addressed in the next section. Increasing age is the 
strongest and most consistent risk factor for VTE in the general population, and the annual 
risk is observed to increase exponentially from  0.1 per 1000 in adolescence to 6-10 per 1000 
at high age (13, 14, 24, 116). The reason for increased risk of VTE by age is unknown, but 
thickening of the venous valves (117), decreased muscle tone and accumulation of co-
morbidities including malignancy have been suggested as potential underlying causes (53). A 
higher risk has been observed in young women compared to men (13, 116), and has been 
attributed to reproduction-associated factors and the use of oral contraceptives in younger 
women (118, 119). In middle-aged and elderly, an increased risk has been noted in men (13, 
116, 120). Interestingly, this difference between genders was eliminated when the risk 
estimate was adjusted for body height (120). Recently, it has also been emphasized that 
after taking reproduction-associated factors in women into account, men have a 2-fold 
higher risk also at young age (121). Body height has been demonstrated to be an 
independent risk factor for VTE (120, 122, 123), and 30 % higher risk of VTE per 10 cm 
increase in height has been noted in men (123). Obesity, measured by body mass index 
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(BMI) ≥ 30 kg/m2, provides a 2-3 fold increased risk of VTE (122, 124-127). In the Tromsø 
study, waist circumference (WC) had the best ability to identify patients at risk of VTE, and 
WCs ≥ 85 cm in women and ≥95 in men were associated with 2- and 3-fold risks, respectively 
(127). Population-based studies that have investigated the association between smoking and 
VTE have reached diverging conclusions (125, 128, 129). A recent meta-analysis concluded 
that smoking is a weak but independent risk factor for VTE, and emphasized that studies that 
did not control for BMI tended to report lower estimates (130). However, in a previous 
report from the Tromsø Study, the 1.5 fold increased risk of VTE by heavy smoking (≥ 20 
pack-years) disappeared when cancer and myocardial infarction were taken into account in a 
competing risk model (131). Thus, the risk of VTE by smoking remains controversial and 
should perhaps be further investigated in populations with and without these diseases.  
It has been demonstrated that family history of VTE provides a 2-3 fold increased risk 
of VTE (132-136), and family studies have estimated that 50-60 % of the variation in 
susceptibility to develop VTE can be attributed to inheritance (137-139). Since the first 
discovery in 1965 (140), a number of inherited risk factors have been identified (141). 
Thrombophilia may be caused by increased function of natural procoagulants or impeded 
effect of the anticoagulants. So-called gain of function thrombophilia include Factor V Leiden 
(FVL), prothrombin G20210A and non-O blood groups. Heterozygote FVL is present in 
approximately 5 – 8 % of the population (128, 142, 143) and is more common in northern 
Europe. FVL is caused by a missense mutation of the Factor V gene which makes the cofactor 
insensitive to activated protein C (APC), and heterozygote carriers have a 2-5-fold increased 
risk of VTE compared to non-carriers (141, 144). Prothrombin G20210A is a polymorphism 
associated with increased levels of prothrombin and regulation of the anticoagulant pathway 
of APC. The variant is found in 1-2 % of the population (143, 145) and is associated with a 
  
  27 
 
1.5-3 fold increased risk of VTE (144). The non-O blood groups are the most common 
inherited risk factors as they are found in ~ 60 % of the population (143). Due to decreased 
clearance of non-O vWF, subjects with these blood types have higher levels of vWF and FVIII 
(146) and a 1.5-2 fold higher risk of VTE compared to blood group O (141, 143). However, 
blood type remains an independent risk factor for VTE after adjustment for plasma levels of 
vWF and FVIII (147, 148), and implies that the thrombotic risk in subjects with non-o blood 
groups also may be mediated through additional unknown pathways. Protein C, -S and 
antithrombin deficiencies constitute the loss of function thrombophilia. These deficiencies 
are associated with higher risk, and are termed severe thrombophilia. Antithrombin (AT) 
deficiency was first described in a mother (39 years) and her son (13 years) from Skjervøy 
both experiencing VTE by the Norwegian physician Olav Egeberg in 1965 (140). AT is a potent 
inhibitor of several steps of the coagulation cascade (thrombin, FXa, FIXa), and is further 
enhanced by administration of heparins. Regardless of the high number of identified 
mutations (>340), AT deficiencies are rare (~0.02 %) and are associated with about 10-50 
fold increased risk of VTE (144). Protein C and S deficiencies, discovered in the 80s (149, 
150), provide risks of similar magnitude (~10-fold), however they too are rare and occur in 
only 1-5 per 1000 in the population (151).  
Inherited risk factors can be modified by the presence of other genetic or 
environmental factors, and is referred to as gene-gene or gene-environment interactions. 
For instance, more excess cases were observed in obese carriers of FVL than in the non-
obese (122, 128). The effect was described as an interaction on an additive scale. Similarly, 
smoking appears to provide higher excess risk among FVL carriers than non-carriers (128, 
152). Positive gene-gene interactions are also common. One example is the high risk of VTE 
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noted in subjects with both FVL and prothrombin 20210A polymorphism, where a 20-fold 
increased risk has been demonstrated (153).  
Despite increasing knowledge of the inherited risk factors, it has been estimated that 
known mutations only account for 5 % of the observed heritability (154). In coherence, 
family history remained an independent risk factor for VTE after consideration of common 
inherited risk factors (133). Epigenetics, unrecognized mutations and interactions may be 
underlying explanations. Genome-wide association studies have detected weak genetic 
mutations that are frequent in the population (e.g. single nucleotide polymorphisms; SNPs). 
Ongoing and future genomic studies will presumably increase the knowledge on genetics in 
thrombosis. 
Venous thromboembolism is a multicausal disease, meaning that several risk factors 
need to be present for a thrombus to develop. The concept is well explained by the potential 
model for thrombosis (155), which illustrates how individual risk factors, such as high age 
and FV Leiden, alone may not be sufficient for formation of a thrombus. Under high-risk 
situations however, these intrinsic risk factors contribute to reach a threshold where the 
physiological anticoagulant properties are outweighed by the hypercoagulable state, 
resulting in thrombosis.  The model also demonstrates the acute pathogenesis of VTE. Unlike 
arterial plaque formation which evolves throughout life, incident VTE occur when 
accumulation of factors leads to a sudden imbalance between the natural pro-and 
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Figure 2. The thrombosis potential 
model. The green line represents 
an intrinsic risk factor such as 
factor V Leiden (FVL), and the red 
line represents the effect of age 
alone. The purple line 
demonstrates the effect of age 
and FVL, in combination with 
provoking factors early and late in 
life, respectively. The latter 
combination reaches the 
thrombosis threshold and the 
person develops symptomatic 
VTE.   
 
 
1.3.2 Cancer-related risk factors 
A number of cancer-specific factors may lead to the hypercoagulable state observed 
in cancer patients, and several factors are often present at the same time. Characteristics 
like cancer site, stage, treatment modality and age are highly correlated. Since all these 
factors also influence the risk of thrombosis, it can be difficult to determine the effect of the 
individual contributors.   
Chemotherapy is a well-established risk factor for VTE (156). In a nested case-control 
study from the US (36), the risk for VTE by malignant disease was increased from 4-fold to 
6.5-fold in patients who received chemotherapy, and in a large cohort of cancer patients 
from the Netherlands, chemotherapy was associated with a 2 fold increased risk of VTE (44). 
In a case cross-over study from the United States, chemotherapy was identified as an 
important trigger of hospitalization for VTE and was associated with a 6-fold increased risk 
(157). A randomized study showed high excessive risk of VTE in breast cancer patients who 
were assigned to 6 months of chemotherapy in addition to tamoxifen in comparison to 
treatment with tamoxifen alone (14 % and 2.6 %, respectively) (158). Khorana and co-
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workers reported an absolute VTE risk of 2.2 % after a median follow-up of 2.5 months 
(range 5-364 days) in a study of 4066 outpatients included in ANC Study Group Registry (42). 
Two smaller studies found higher rates of VTE; 7 % during or within 3 months (159) and 8 % 
within 35 months after chemotherapy (114). Various chemotherapeutic agents affect the 
risk of VTE differently, and certain combination regimens are known as highly thrombogenic. 
Cisplatin-based agents provided higher risk for thrombosis than oxaliplatin (12 % and 6.5 % 
within one month after discontinuation, respectively) in a randomized trial of patients with 
gastro-esophageal cancers (160). Thalidomide with concomitant high-dose steroid therapy 
and/or chemotherapy in patients with multiple myeloma has been associated with 
particularly high risk of VTE (161-164). A meta-analysis showed 30 % increased risk of VTE in 
patients treated with the angiogenesis inhibitor bevacizumab (165). 
 Several potential mechanisms may explain the risk of VTE observed during 
chemotherapy. First, chemotherapeutic agents can cause endothelial injury. Lysis of tumor 
cells, endothelial cells or circulating blood cells may cause release of various cytokines with 
prothrombotic potential. Cell free DNA has been suggested as a novel procoagulant 
stimulus, and has been shown to rise 24 hours after administration of chemotherapy (166). 
Chemotherapy have also been proposed to activate blood platelets directly through the 
arachidonic acid pathway (167). Implanted ports, bed rest and reduced performance status 
as well as neutropenia and infections may further enhance the VTE risk during 
chemotherapy. Somewhat surprisingly, two studies have failed to demonstrate increased 
levels of circulating MPs in subjects with chemotherapy-related VTE (168, 169).  
Several acute infections have been associated with a higher risk of VTE (170-172), 
and infection has been emphasized as an important risk factor for VTE in cancer patients 
(173). A particularly high risk of VTE was reported in a study of neutropenic cancer patients 
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(40), and multiple neutropenic episodes have been associated with increased risk of 
recurrent VTE in oncology patients (174). Neutropenia is closely related to infection, and 
abovementioned results might imply that infectious diseases in patients with malignancy 
exhibit a particular thrombotic risk.  
  VTE is a frequent complication of surgery in both cancer and non-cancer patients. 
Heit and colleagues reported that recent institutionalization with and without surgery were 
associated with 22- and 8-fold increased risks of VTE, respectively (36). A 2-3 fold higher risk 
of VTE and fatal PE following surgery for cancer compared to surgery in non-cancer patients 
(9, 175-177) and a 30-day cumulative risk of 1.6 % have been reported after cancer surgery 
(178). Surgeries for gastrointestinal, lung, prostate and gynecological cancers were high risk 
procedures, and the risk was particularly high in older patients, in those with congestive 
heart failure, obese patients or in patients with ascites, and in subjects with preoperative 
thrombocytosis. Operation time > 6 hours was associated with a 4-fold increased risk 
compared to a duration < 2 hours. A nationwide study from the UK reported an in-hospital 
VTE rate of 1.3 % after major cancer surgery (177). However, 30-60 % of postoperative VTE 
occur after hospital discharge (175, 178, 179). Extended LMWH prophylaxis beyond the 
hospital stay has been tested in several trials of cancer and non-cancer patients, and has 
been reported to reduce the risk of VTE without any substantial increase in bleeding 
complications (180). In the 9th edition of the American College of Chest Physicians guidelines 
for prevention of VTE, the recommendation for extended prophylaxis (4 weeks 
postoperatively) after cancer surgery was strengthened (Grade 1B in 2012 vs. 2A in 2008) 
(180).   
Immobilization is a recognized provoking factor for venous thromboembolism (181). 
In a case-control study of cancer-free subjects aged > 70 years, immobility-related risk 
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factors (e.g. hospitalization, surgery, fractures, plaster cast use, minor injuries and transient 
immobility at home) accounted for 40% of the VTE events (182). A meta-analysis of 36 
cohort studies and seven case-control studies found that immobilization was associated with 
an overall 2-fold risk of VTE (183), and in a case-crossover study from 2012, immobilization 
provided a 4-fold increased risk of hospitalization with venous thrombosis (157). Due to the 
non-randomized distribution of bed-rest among patients, the sole impact of immobilization 
is difficult to separate from the underlying cause of bed-confinement. However, the 
biological rationale for a true association is strong.  In healthy individuals, the venous 
pressure decreases during exercise due to the muscle pump activity, and venous emptying is 
facilitated by high muscle mass (184). A supine position prohibits the use of the muscle-vein 
pump, and may induce stasis and vessel-wall hypoxia. Furthermore, muscle mass rapidly 
decreased during bed-rest. It is possible that this causes inadequate venous emptying also in 
the period after prolonged immobility. The increased risk of VTE observed after long-haul 
travel (185, 186) and in patients with stroke (187-189) further strengthens the evidence of a 
causal relationship between immobility and VTE. Immobilization is common in cancer 
patients, especially during active treatment and at end-stage disease, and may be 
responsible for a high proportion of cancer-associated VTE.   
Venous ports and indwelling central venous catheters (CVC) for administration of 
chemotherapy are associated with an increased risk of upper-extremity DVT, and are often 
considered as a provoking factor (190). The frequency of upper limb DVT varies greatly 
between studies, and ranges from 4-40 % (191-196) . A recent Canadian study followed 400 
cancer patients with newly implanted ports who did not receive thromboprophylaxis. Within 
a median of 12 months, 8.5 % were diagnosed with VTE. Men had a 2-fold increased risk 
compared to women, and PE was equally common as DVT (197).  
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 The majority of studies of cancer-associated VTE are based on data from health 
registries.  While cancer-associated factors such as cancer stage and treatment often are 
available in such registries, and co-morbidity data can be obtained by discharge diagnosis 
codes, other patient characteristics can normally not be provided. As a consequence, the 
impact of the conventional VTE risk factors observed in cohort-studies of the general 
population has only been evaluated in a few studies of cancer-associated VTE. Little is known 
about the joint effect of cancer and risk factors such as lifestyle habits and anthropometric 
measures, or whether the effect is constant across cancer sites. Prothrombotic mutations 
are probably also important determinants of cancer-associated VTE. Results from the MEGA 
study revealed that Factor V Leiden or prothrombin 20210A mutations further increased the 
VTE-risk in patients with cancer (35).  
Several studies have evaluated the effect of high age on the risk of VTE. While the 
effect of increasing age at population-level is clear, the impact of high age in cancer-cohorts 
is inconclusive. A large study of hospitalized cancer patients found virtually similar rates of 
VTE among patients aged 40-59 years and 60-79 years (41). In the registry-based cohort 
study of cancer patients by Chew et al (45), they found an overall positive association 
between high age and VTE. However, the age-effect differed across cancer sites and the 
association was not positive for all cancer sites. Among cancer patients included in the 
Danish cohort by Cronin-Fenton et al (34), the overall effect of age was also positive. In this 
cohort, young and elderly patients had similar risk in the first year after cancer diagnosis, 
whereas the average risk during the entire follow-up was higher among the elderly. High age 
was noted as an important risk factor for cancer-associated thrombosis in a study of 
neutropenic cancer patients (40). However, the increased risk by age was mainly due to high 
risk of arterial thrombosis in the elderly, and age had little influence on the risk of VTE. 
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Finally, the ANC Study Group found that the risk of VTE was independent of age in their 
cohort of ambulatory cancer patients (42). Taken together, previous findings are inconsistent 
and it is not known whether high age should be emphasized as an independent risk factor 
for cancer-associated VTE.  
   
1.4 Risk stratification for cancer-related venous thromboembolism 
1.4.1 Biomarkers 
A biomarker is a laboratory parameter with diagnostic or prognostic value. As 
opposed to a risk factor, which in the general sense is causally associated with the outcome, 
a biomarker can be causally or non-causally associated with the disease. A good biomarker 
has high sensitivity and specificity for the outcome of interest. Knowledge about biomarkers 
for cancer-associated VTE has mainly been provided by two prospective cohorts; namely the 
ANC Study Group Registry (42) and the Vienna Cancer and Thrombosis Study (CATS) (43). 
The ANC Study Group Registry includes approximately 4000 cancer patient followed through 
maximum four cycles of chemotherapy, with baseline measurements obtained prior to 
initiation of chemotherapy. Biomarkers for chemotherapy-associated VTE identified in this 
cohort were leukocytosis (> 11 x 109 /L), thrombocytosis (≥350 x 109/L) and anemia 
(hemoglobin < 10 g/dl).  In CATS, 819 patients recently diagnosed with incident cancer or 
relapse were followed for a median of almost two years. Increased risk by elevated platelet 
count (above the 95th percentile) was confirmed in this cohort (112). Additionally, P-selectin, 
d-dimer, prothrombin fragment 1+2 and factor VIII level have been reported to further 
increase the VTE-risk among the CATS participants (198-200). Biomarkers for prediction of 
venous thrombosis in cancer patients have recently been summarized in a review by 
Pabinger and colleagues (201).  
  
  35 
 
In agreement with the findings from the ANC Study Group Registry, leukocytosis was 
associated with VTE among patients enrolled in RIETE registry (202). The study revealed a 60 
% increased risk of recurrent VTE among cancer patients with leukocytosis at the time of the 
acute VTE. Conversely, the association between leukocyte count and VTE, measured by a 
doubling in the white blood cell (WBC) count, could not be confirmed in CATS (112). 
However, the CATS study is a quite small study with only 62 VTE events, and the lack of 
association may be due to low power.  
D-dimer is a degradation product of cross-linked fibrin, and is elevated during 
ongoing coagulation and fibrinolysis. Elevated d-dimer is a sensitive but non-specific marker 
of VTE (203, 204) that plays an important role in VTE diagnostics (205).  D-dimer levels are 
increased in cancer patients compared to controls and have been found to predict VTE in 
patients with cancer. Since the predictive value of a negative test is inversely associated with 
the incidence, the negative predictive value will presumably be high in asymptomatic cancer-
patients as compared to subjects admitted to hospital with typical signs and symptoms. The 
highest HR for VTE in patients with elevated d-dimer was demonstrated in lung cancer 
patients, with a HR of 11 (cut-off >1.5 µg/ml) (206), and several other studies have reported 
positive results (199, 207-209).  The CATS study observed an almost doubled risk of VTE in 
patients with elevated d-dimer at inclusion (199).  
The CATS study group also demonstrated that P-selectin above the 75th percentile 
was an independent risk factor for cancer-associated VTE with a HR of 2.6 (198). P-selectin is 
an adhesion molecule stored in α-granules of platelets and Weibel-Palade bodies of 
endothelial cells, and is a recognized marker of activated platelets and endothelial cells. P-
selectin has also been associated with VTE in patients without cancer (210).  
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 Other biomarkers suggested for cancer-associated VTE are TF+ MPs, factor VIII and 
estimated glomerular filtration rate (eGFR). In 2007, Tesselaar and co-workers observed an 
association between TF+ tumor-derived MPs (TMP) and VTE in a retrospective study of 40 
patients with breast or pancreatic cancers (211). The majority of later studies have 
confirmed the finding, and prospective studies have indicated that the increased level of TF+ 
MP precedes the onset of thrombosis (106). Conversely, two prospective studies, including 
CATS, did not observe an association between TF+ MPs and VTE (212, 213). It has been 
hypothesized that an early collection of blood samples may explain the lack of association in 
these studies. CATS had a 2-year follow-up after the baseline blood sample, and would not 
capture a potential increase in TF+ MPs activity occurring closer to the thrombotic event 
(213). An ongoing study in patients with advanced cancers uses repeated blood samples and 
may clarify the predictive properties of TF+ MPs in cancer-associated VTE (106). 
 In coherence with the increased risk of bleeding in patients with factor VIII deficiency 
(i.e. hemophilia A), increased levels of factor VIII has been emphasized as an independent 
risk factor for VTE in several case-control studies (214-220). Factor VIII is bound to vWF in 
the circulation, and serves as a cofactor to factor IXa in the activation of factor X. Increased 
levels of factor VIII has been noted in various cancers (221-223). In the CATS population, high 
factor VIII levels showed an age-dependent association with VTE, which ranged from 2-fold 
in young to a non-significant 20 % increased risk in the elderly (224).  
 Recently, reduced eGFR was demonstrated to exhibit a 3-fold increased risk of 
subsequent VTE in cancer patients who underwent chemotherapy, and has been proposed 
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1.4.2 Prediction models and prophylaxis 
Patients with cancer form a heterogeneous group and the risk of VTE varies 
accordingly. Risk stratification is needed to obtain an optimal risk-benefit strategy for 
pharmacological prevention of VTE. Hospitalization for medical illness, major cancer surgery 
and treatment with chemotherapy are the main high-risk situations were prophylaxis should 
be considered. Risk assessment models (RAMs) for various settings have been suggested and 
include the Khorana model and the Padua Prediction Score (Table 2a and b). The Khorana 
model (42) was developed and validated in an outpatient cohort who received 
chemotherapy. The model assigns points for five clinical and laboratory parameters, and 
high risk scores (≥ 3 points) and the absence of contraindications suggests that prophylaxis 
may be beneficial. Points are assigned for very-high and high risk cancer sites (2 and 1 point, 
respectively), pre-chemotherapy leukocyte-, platelet- and hemoglobin level (anemia or use 
of erythropoiesis-stimulating agents (ESAs)), as well as obesity measured by BMI ≥ 35 kg/m2. 
Overall, 2 % developed VTE during the 2.5 months of follow-up. In the validation cohort (one 
third of the cohort), the model had a negative predictive value of 98.5%, while the absolute 
risk (positive predictive value) of VTE among patients with ≥ 3 points was 7 %. Patients with 
brain-, renal- and myeloma cancers were not included in sufficient numbers, and their 
allocation (i.e. normal, high risk or very high risk) could not be determined in the study. 
Performance status showed only a weak, non-significant association with VTE, but a small 
proportion of the cohort had poor performance status and the lack of a clear association 
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Table 2 
a)                                                                                      b) 
 
 
Ay and colleagues suggested that soluble P-selectin and d-dimer should be included 
in an extended version of the Khorana model (43). The cumulative risk at 6 months among 
patients with the two highest scores (score 4 and 5, capturing about 10% of the participants) 
was 25% and 35 %, respectively. When the original Khorana model was applied in this 
cohort, the risk was 18 % at 6 months. Thus, addition of the two biomarkers further 
increased the positive predictive value of the Khorana model, but the cost-effectiveness is 
unclear. The overall higher frequency of VTE in the latter cohort (7.4 % vs. 2.1 %) was 
probably due to prolonged follow-up, as well as the inclusion of more high-risk cancer sites, 
(such as pancreas, brain and gastric cancer). 
 A post hoc analysis of the participants of the Protecht-trial was performed to assess 
the impact of chemotherapy (cisplatin- or carboplatin-based, or gemcitabine) on VTE-risk 
(227). Based on the use of these agents together with the parameters of the Khorana model, 
patients were defined as low- or high-risk patients. More than 30 % of the patients were 
Padua Prediction score (226) 
Patient characteristics 
Risk score 
Active cancer  3 
Previous VTE  3 
Reduced mobility 3 
Known thrombophilic condition 3 
Recent (≤ 1 mo) trauma and/or 
surgery 
2 
Elderly age (≥ 70 y) 1 
Heart and/or respiratory failure 1 
Acute myocardial infarction or 
ischemic stroke 
1 
Acute infection and/or 
rheumatologic disorder 
1 
BMI ≥ 30 kg/m2 1 
Ongoing hormonal treatment 1 
The Khorana model (42) 
Patient characteristics 
Risk score 
 Site of cancer  
 Very high risk (stomach, 
pancreas) 
2 
 High risk (lung, lymphoma, 
gynecologic, bladder, testicular) 
1 
Prechemotherapy platelet count         
≥ 350 x 109/L 
1 
Prechemotherapy hemoglobin level   
< 10 g/dL or ESA use 
1 
Prechemotherapy leukocyte count     
> 11 x 109/L 
1 
BMI ≥ 35 kg/m2 1 
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termed as high-risk by the Protecht score (compared to 12 % by the Khorana model), and 67 
% of the VTE events occurred in this group (compared to 33 % by the Khorana model). 
VTE prediction among hospitalized cancer patients has been less thoroughly 
investigated. A comparison of three different RAMs for hospitalized patients (i.e. Kucher, 
Harinath and St. Johns) (228) found that the models had different accuracy according to 
department, and that the Kucher RAM (229), which is used in North-American hospitals, was 
superior in oncology patients. However, none of the RAMs for hospitalized patients were 
developed for cancer patients in particular, and high age was included in all of the models (> 
40 in the Harinath and St. Johns, > 65 in Kucher, and > 70 in the Padua score).  As previously 
emphasized, studies conclude differently with respect to age in cancer-associated VTE. For 
appropriate VTE prevention in cancer patients, it is important that the role of high age is 
established.  
 Current guidelines suggest prophylaxis for high risk out-patients and selected medical 
patients, and recommends extended prophylaxis in cancer patients who undergo major 
surgery. The effect of prophylaxis has been evaluated in clinical trials of outpatients with 
cancer, and was found to reduce the rate of VTE in these patients. However, the VTE rates in 
the trials were low, and the number needed to treat (NNT) to save one VTE event ranged 
from 50-100 (38, 39). Use of RAMs and targeted prophylaxis have not been formally tested, 
but will necessarily reduce over-prophylaxis. Application of the Khorana score and the 
Protecht score was estimated to reduce to NNT from 50 to less than 20 (227). The number of 
cancer-patients has been limited in trials of hospitalized patients, and the safety of 
prophylaxis in these settings has not been evaluated in cancer patients. Thus, the risks and 
benefits of pharmacological prophylaxis in hospitalized cancer patients are not known (230).  
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2       AIMS OF THE STUDY 
 
Although cancer-associated VTE has been addressed in many studies, large population-based 
cancer cohorts with validated end-points and information about potential confounders have 
been lacking in the epidemiological description of the disease. Patients with cancer have a 
high-risk of VTE, and risk stratification and targeted pharmaceutical prevention is warranted. 
These aspects stress the importance of reliable estimates of the disease-burden as well as 
the impact of various cancer- and patient-related factors on cancer-associated VTE.  
 High levels of leukocytes and platelets are predictive of VTE in oncology patients. 
However, characteristics such as cancer stage and comorbidities may influence the cell 
counts, and it is therefore not known whether high levels of these cells are causally related 
to VTE or merely reflect concomitant risk-factors. Baseline measurements prior to cancer 
development may yield a better understanding of the role of blood-count parameters in 
cancer-associated VTE. 
 
The aims of the study were:  
1. To assess the incidence of cancer-associated VTE in age-groups, and determine 
whether the increased risk of VTE in the elderly could be attributed to cancer. 
2. To assess the incidence of cancer-associated VTE and attributable risks by cancer-
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3. To investigate the impact of pre-cancer leukocyte and neutrophil counts on the risk 
of VTE in subjects who subsequently develop cancer and in those who remain cancer 
free.  
4. To investigate the impact of pre-cancer platelet count on the risk of VTE in subjects 
who subsequently develop cancer and in those who remain cancer free.    
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3 METHODS 
3.1  Study populations 
3.1.1 The Tromsø Study 
The Tromsø Study is a prospective, population-based study with repeated health 
surveys of the adult population in Tromsø. Since the first survey in 1974, five surveys has 
been conducted, the most recent in 2007-2008 (231). The Institute of Community Medicine 
at the University of Tromsø is responsible for the study, and the seventh survey is now under 
planning. The study was originally conducted due to the high frequency of myocardial 
infarction in the northern Norway. Additional outcome registries, including the VTE registry, 
have been established subsequently.  
 The largest survey (Tromsø IV) was carried out in 1994-95. All inhabitants of the 
municipality of Tromsø aged > 24 years were invited to participate and 27 158 subjects 
participated (77 % of the invited population). Papers I, III and IV are based on Tromsø IV, 
whereas paper II includes two additional Scandinavian cohorts.  
 
3.1.2 The Scandinavian Thrombosis and Cancer Study  
The Scandinavian Thrombosis and Cancer (STAC) Study is a merged cohort which 
consists of three longitudinal cohort studies, namely the Tromsø IV (Norway), the Health 
Survey in Nord-Trøndelag (HUNT) (Norway) and the Diet, Cancer and Health (DCH) Study 
(Denmark). A detailed description of the study population is found in paper II. The HUNT 
study invited all adults aged > 19 years, whereas only middle-aged subjects (50-65 years) 
without a history of cancer were included in DCH. Enrollment of study participants took 
place between 1993 and 1997. The studies were approved by the respective ethical 
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committees in Tromsø and Trøndelag (Norway) and Copenhagen and Aarhus (Denmark), and 
subjects gave their informed written consent to participate. The individual populations 
counted 26 856 (Tromsø Study), 65 174 (HUNT II) and 56 014 (DCH), and after exclusion of 
subjects with a history of cancer or missing data, the merged cohort consisted of 137 273 
subjects.   
 
3.2  Cancer ascertainment  
Information about cancer was obtained by linkage to the cancer registries in Norway 
and Denmark. The Cancer Registry of Norway (CRN) and the Danish Cancer Registry are 
similarly organized and receive notifications from several medical sources including hospital 
doctors, general practitioners, pathological laboratories and death certificates. The Danish 
Cancer Registry was linked to the national hospital discharge registry in 1987, and included 
outpatient diagnoses since 1995 for additional completeness. In Norway, discharge 
diagnoses for hospital- and outpatient care have only been included since 1998. Reporting 
has been mandatory since 1987 in Denmark (232)  and 1952 in Norway (233). In Norway, 
physicians who fail to report a case (i.e. to send the clinical notification) within two months 
after a diagnosis has been reported from another source (e.g. pathologists, patient discharge 
records or mortality sources), will receive a reminder from the cancer registry. For each case, 
the cancer registries aim to provide the date of diagnosis, primary site (ICD-7/ICD-10), 
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3.3 Baseline measurements  
Baseline measurements in Tromsø IV were applied as potential confounding variables 
in papers I and II, and provided the exposures of interest in papers III and IV. The information 
was obtained by physical examination, self-administered questionnaires and non-fasting 
blood samples. Anthropometric measures were obtained with subjects wearing light clothing 
and no shoes. Body mass index was calculated as the weight in kilograms divided by the 
squared height in meters (kg/m2). Blood pressure was recorded by trained personnel using 
an automatic device (Dinamap Vital Signs Monitor). After 2 minutes of sitting rest, the blood 
pressure was recorded three times by 2-minute intervals, and the average of the two last 
readings was used in the analyses. Non-fasting blood samples were collected from the 
antecubital vein and analyzed by the Department of Clinical Chemistry. For mean platelet 
volume (MPV) and white blood cell-, neutrophil- and platelet counts 5 ml of blood were 
collected into Vacutainer tubes with EDTA as an anticoagulant (K3-EDTA 40 µL, 0.37 mol/L 
per tube) and analyzed by an automated blood cell counter (Coulter Counter®, Coulter 
Electronics, Luton, UK) within 12 hours. Information about previous atherothrombotic 
diseases (i.e. myocardial infarction, angina and stroke), diabetes and current use of 
antihypertensive medicine were obtained from self-administered questionnaires. Smoking 
status, alcohol consumption and physical activity level were also collected. Smoking habits 
were assessed by current daily smoking of cigarettes, cigars or pipe (i.e. yes/no for each 
question), the number of daily cigarettes and years of daily smoking for former and current 
smokers, as well as the time since smoking cessation for former smokers. The English 
translation of the original questionnaires are presented in the Appendix.    
 Acquisition of baseline data in the HUNT study and the DCH study was similarly 
performed, and has been described in detail elsewhere (234, 235). 
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3.4 Registration and validation of venous thromboembolism  
VTE events were similarly recorded and validated in the three cohorts, and 
symptomatic, first life time VTE events were included. In the Tromsø Study, VTE events were 
identified by searching the hospital discharge diagnoses registry, the radiology procedure 
registry and the autopsy registry at the University Hospital of North Norway. Relevant 
International Classification of Diseases, revision 9 (ICD-9) codes for the period 1994-1998 
were 325, 415.1, 452, 453, 671.3, 671.4 and 671.9, and ICD-10 codes for the period 1999-
2010 were I26, I80, I81, I82, I67.6, O22.3, O22.5, O87.1 and O87.3. For the cases identified 
by discharge codes or the radiology registry, the VTE events were included when typical 
signs and symptoms of VTE were described in the medical record, objective diagnostic tests 
were performed (e.g. compression ultrasonography, venography, spiral computed 
tomography, perfusion-ventilation scan and pulmonary angiography) and a diagnosis was 
made in the medical record. Unless contraindications were specified in the medical journal, 
treatment with anticoagulants, thrombolytics or vascular surgery was also required for 
verification. VTE events identified from the autopsy registry were included when VTE was 
described as the cause of death or a significant condition in the autopsy record.   
In the Danish cohort, cases were identified by linkage to the Danish National Patient 
Registry and the Danish National Death Registry by use of the personal identification number 
(128). The events were validated by similar abovementioned confirmatory criteria in the 
patient medical records. In addition, echocardiography was among the confirmatory 
diagnostic tests for PE. Events that were identified through the cause of death statistics (i.e. 
National Death Registry) were included only if VTE was confirmed by autopsy.   
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VTE events in the HUNT study were identified from discharge codes from the two 
hospitals in the region and procedure codes from the respective radiology departments. 
Each case was verified by objective criteria described in detail elsewhere (13). 
A VTE event was classified as either DVT or PE, and when they occurred concurrently 
the event was classified as PE. VTE cases were further classified as provoked or unprovoked. 
Provoking factors were defined slightly differently across the studies. In all the three studies 
provoking factors included cancer at the time of the VTE event, surgery, trauma, long haul 
travel, acute medical conditions, immobilization and other factors like central venous 
catheters prior to the event. Pregnancy/puerperium and oral contraceptive use were 
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4  MAIN RESULTS 
4.1  Paper I 
THE INCREASED RISK OF VENOUS THROMBOEMBOLISM BY ADVANCING AGE CANNOT BE 
ATTRIBUTED TO THE HIGHER INCIDENCE OF CANCER IN THE ELDERLY: THE TROMSØ STUDY 
 
 
It has been suggested that the increased risk of VTE in the elderly may be due to a higher 
frequency of cancer, but the statement has not been formally tested. We used a prospective 
population-based cohort with validated VTE events to assess the adjusted impact of cancer 
on the risk of VTE across age-strata, and to estimate the attributable proportions in young, 
middle-aged and elderly. Subjects were recruited from the fourth survey of the Tromsø 
Study, and cancer was treated as a time-dependent exposure counted from 1 year prior to 
the date of cancer diagnosis. Cancer was substantially more common at higher age, and the 
rates were 1.8 per 1000 person-years (PY) in those < 50 years and 22 per 1000 PY in those ≥ 
70 years. VTE was recorded in 138 of the 2 290 subjects with cancer, whereas 393 events 
occurred among 26 094 unexposed subjects. The crude incidence rate (IR) for cancer-
exposed subjects was 13 per 1000 person-years (PY), compared to 1.2 per 1000 PY among 
the cancer-free. The rate of VTE by overt cancer increased from 9 per 1000 PY in young to 15 
per 1000 PY in the elderly.  Despite the high frequency of cancer in the elderly, the 
attributable proportion was highest in middle-aged, where cancer explained 27 % of the 
events in the population. Corresponding proportions in young and elderly were 14 and 18 %, 
respectively. The hazard ratio (HR) for VTE by cancer was 5.5 for all ages combined, and 
declined from 26-fold in young to 3-fold in the elderly. Despite higher proportion of potential 
confounders in cancer patients, the HRs were not attenuated by inclusion of these variables 
in the multivariable Cox-model.  Our results imply that cancer cannot explain the increased 
risk of VTE at higher age.  
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4.2  Paper II 
CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM IN A GENERAL POPULATION – THE 
SCANDINAVIAN THROMBOSIS AND CANCER (STAC) STUDY 
 
Previous population-based cancer cohorts are mainly based on registry data and risk 
estimates may be biased by incomplete outcome registration and lack of VTE validation. 
Potential confounders of the association between cancer and VTE such as smoking and body 
mass index have not previously been addressed in overall- and site-specific risk assessment.  
We performed one-level analyses of three population-based Scandinavian cohorts including 
a total of 137 273 subjects that were followed from inclusion (1993-1997) to 2010 at the 
most. Cancer exposure accrued from the date of diagnosis until VTE, death, migration or end 
of follow-up. Site-specific incidence rates (IRs) of cancer-associated VTE were assessed per 
1000 person-years (PY), and hazard ratios were calculated by adjusted regression models 
with age as timescale and cancer-free subjects as reference.  A total of 1.6 % developed VTE 
within the first year after cancer diagnosis. Close to 20 % of the VTEs in the population could 
be attributed to cancer, and cancer of the lungs, bowel and prostate were responsible for 
more than 40 % of the cancer-associated VTE events. The crude rate of VTE in the cancer 
cohort was 8.7 per 1000 PY corresponding to an adjusted HR for VTE by cancer of 4.9 (95 % 
CI; 4.4-5.5). However, there was a strong temporal relation between the cancer diagnosis 
and VTE, and IRs and HRs declined by increasing the duration of follow-up. This effect was 
most pronounced in cancers with low mortality. In conclusion, the adjusted HRs for cancer 
overall and within cancer sites were similar to those previously reported. However, risk 
estimates assessed from long-term follow-up appear to be influenced by site-specific 
mortality, and underestimate the risk in cancers with better prognosis. 
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4.3  Paper III 
WHITE BLOOD CELL COUNT MEASURED PRIOR TO CANCER DEVELOPMENT IS ASSOCIATED 
WITH FUTURE RISK OF VENOUS THROMBOEMBOLISM – THE TROMSØ STUDY 
 
An increased risk of VTE has been demonstrated in cancer patients with elevated leukocyte 
count. However, as inflammation due to aggressive cancer or concomitant infection is 
associated with leukocytosis as well as VTE, previous studies do not allow for causal 
inference. To investigate a potential causal relationship between high leukocyte count and 
VTE in malignancy, we used a prospective population-based study where WBC- and 
neutrophil counts were collected prior to cancer development. We assessed the risk of VTE 
by categories of WBC- and neutrophil count in subjects who developed cancer and in 
subjects who remained cancer-free.  24 304 initially cancer-free subjects were recruited 
from the fourth survey of the Tromsø Study. A total of 388 VTE events were recorded from 
inclusion to end of follow-up (September 1st 2007), of which 116 events occurred among the 
1720 subjects who developed cancer. In the cancer cohort, baseline WBC count above the 
80th percentile (≥8.6 x 109 cells/L) provided a 2.4-fold increased risk of VTE compared to 
subjects with WBC count below the 40th percentile (HR 2.36,  95% CI:1.44-3.87). Similar 
findings were observed for neutrophil count. Conversely, no association was observed 
between WBC- or neutrophil count in the group of cancer-free subjects. Our results suggest 
that the elevated white blood cell count may play a causal role in development of cancer-
associated VTE. 
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4.4  Paper IV 
PLATELET COUNT MEASURED PRIOR TO CANCER DEVELOPMENT IS A RISK FACTOR FOR 
FUTURE SYMPTOMATIC VENOUS THROMBOEMBOLSIM: THE TROMSØ STUDU 
 
Platelets are important components of the hemostatic system, and elevated platelet count 
has been associated with increased risk of VTE in cancer patients. Since thrombocytosis is 
associated with metastases and inflammation, it is not known whether elevated platelet 
count plays a causal role in development of cancer-associated VTE or merely reflect 
concomitant risk factors. We used a population-based cohort with platelet count measured 
prior to cancer development to investigate the impact of high platelet count on VTE risk 
among subjects who developed cancer and in those who remained cancer-free. Since we 
previously observed that pre-cancer WBC count predicted VTE in patients who developed 
cancer, we also investigated a potential interaction between high platelet and WBC counts. 
25 160 subjects recruited from the fourth survey of the Tromsø study with baseline 
measurement of WBC and platelet count, and without history of cancer or VTE were 
included. There were 2082 subjects who developed cancer during follow-up, and 129 VTE 
events were recorded among these subjects. In the non-cancer population, 377 VTE events 
were registered. The VTE risk by platelet count above the 80th percentile, was increased 2-
fold in subjects who developed cancer (HR 1.93 95 % CI: 1.18-3.16).  The risk of VTE in 
subjects with high platelet and WBC counts were increased 3-fold (HR 2.96 95%CI:1.72-5.08), 
and exceeded the expected combined effect. In conclusion, a high baseline platelet count 
predicted the risk of VTE in patients who developed cancer, but not in those who remained 
cancer-free. The combined effect of high pre-cancer platelet and leukocyte count can be 
described as synergistic.  
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5  GENERAL DISCUSSION 
5.1  Methodological considerations  
5.1.1  Study design 
The four papers in this thesis are based on results from the Tromsø Study, and paper 
II also incorporates two additional population-based cohorts that were merged with Tromsø 
IV. A prospective cohort study is characterized by collection of exposure data prior to 
development of disease with subsequent outcome surveillance. For the three cohorts 
included in this thesis, baseline examinations were performed in the years 1993-1997, and 
development of VTE were registered throughout 2010 at the most. Due to the closed design 
of the cohorts, events such as migration, death, development of VTE or cancer led to a 
progressive decrease in the cancer-free population throughout follow-up. Conversely, 
subjects with cancer at baseline were excluded from the study, and the cancer cohort was 
successively formed during the study period. The observation-time for cancer started at the 
diagnosis date in the national cancer registries, and cancer was treated as a time-dependent 
exposure.   
Cohort studies have several advantages compared to other observational studies. 
Due to the temporal sequence of the exposure and outcome assessment, the presence or 
absence of disease do not influence the exposure status at inclusion. Misclassification of 
exposures in a cohort study therefore tends to be non-differential, and means that recall 
bias for self-reported exposures usually is a minor concern in the cohort design. Similarly, 
since laboratory parameters are collected prior to the outcome of interest, reversed 
causation is generally not an issue. These aspects reduce the chances of type I error (i.e. 
incorrectly rejecting the null-hypothesis) in a cohort study compared to a case-control 
design. However, the high number of subjects required and the prospective follow-up make 
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cohort studies both time consuming and expensive. The cohort study is therefore not 
suitable for rare diseases.  
 
5.1.2  Relative and absolute measures of effect 
The risk of an outcome can be expressed by absolute or relative risk estimates. 
Absolute risks can only be derived from cohort studies. They can be interpreted as 
probabilities and include incidence rates and cumulative risks. Both cumulative risks and 
incidence rates are calculated from the number of new cases in a defined population within 
a given time-frame. However, whereas the denominator of an incidence rate is the sum of 
in-study person-time, the denominator of a cumulative risk is the number of subjects at risk 
at the beginning of the study period. Therefore, when a significant proportion of the 
participants are followed for less than one year, as is often the case in oncology research, 
and the risk of an outcome declines throughout this year, the incidence within the first year 
and the 1-year cumulative risk will differ (i.e. the incidence is higher than the cumulative 
risk). Accordingly, the 1-year cumulative risk of VTE in cancer patients overall was 1.6 %, 
whereas the 1-year rate was 2.0 % in our study. For cancers with high mortality, the 
difference between the two estimates increases accordingly.  
Relative effect measures, such as odds ratios, relative risks and hazard ratios, provide 
the risk among exposed subjects relative to the risk among unexposed. These measures are 
appropriate when evaluating the strength of a causal risk factor, but are highly dependent 
on the risk in the comparison group. The comparison group may represent only a minority of 
subjects at risk in the population, and can be misleading in the clinical setting. Furthermore, 
a relative effect measure is usually relatively low in high-risk populations, for instance among 
elderly, even though the exposure leads to a high absolute number of cases. The main 
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advantage of relative risk estimates is the possibility to adjust for potential confounding 
factors in multivariable regression models. Hazard ratios (HRs) are estimated by use of the 
Cox proportional hazards model (236), and can only be reported in prospective studies 
where time-to-event data is available. A hazard (h(t)) is defined as the instantaneous risk of a 
certain event, given that the subject is event-free at time t, and a HR is read as the ratio of 
the hazard among exposed and unexposed subjects. In contrast, ORs represent the odds of 
exposure among cases (exposed divided by non-exposed) relative to the odds of exposure 
among controls. Odds ratios are usually obtained from case-control studies by univariate 
analyses or logistic regression, and does not take survival-time into consideration. However, 
odds ratios are comparable to relative risks/hazard ratios when the outcome is rare (237).  
Attributable proportions can be calculated from relative risks or incidence rates 
(238). However, when relative risks are applied, the prevalence of the exposure must also be 
known. The prevalence of a disease can be difficult to measure, as it is dependent on both 
incidence and duration. Therefore, attributable risks estimated from incidence rates among 
unexposed and exposed/total population, might be more accurate. Attributable risks were 
estimated in papers I and II, and can be understood as the proportion of a disease in the 
population (PAR%) or among the exposed (AR%) that is explained by the exposure. However, 
for multicausal diseases such as VTE, the interpretation of attributable proportions is not 
straight-forward. Many factors are required for development of disease, whereas 
elimination of one single factor may prevent the disease from occurring. The sum of single 
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5.1.3  Confounding and interaction 
When an association between an exposure and an outcome has been observed, 
several possibilities need to be considered before causality can be inferred; and include 
chance, bias and confounding. A confounding factor is associated with both the exposure 
and the outcome of interest, and is not an intermediate variable in the causal pathway. The 
exposure of interest and the confounding factor may be causally or non-causally associated, 
and leads to uneven distribution of the confounder among exposed and unexposed subjects. 
There are several approaches to investigate the presence of confounding, and the most 
common are stratification and adjustment in a multivariable model (240-242). If the 
observed crude effect disappears within strata of the supposed confounder or after 
adjustment, the crude risk estimate was likely to be explained by one (or several) 
confounding factors. Strong confounders may also turn the direction of the true association 
between the exposure and the outcome. Propensity score models is another method 
increasingly used to evaluate confounding by indication (242-244).The score can be obtained 
by multiple logistic regression, and accounts for differences between groups that may be 
predictors of the exposure status when allocation is not random.   
Subjects who develop cancer might be different from the general population. 
Potential confounders of the association between cancer and VTE include common risk 
factors such as obesity and heavy smoking, comorbidities and cancer-related factors such as 
surgery, hospitalization and chemotherapy. However, cancer-related factors can also be 
regarded as intermediates of the causal pathway. In an analysis to assess the overall impact 
of malignancy in a population, adjusting for the latter factors may lead to over-adjustment, 
which would obscure the full impact of malignancy on VTE-risk. The multivariable models 
presented in paper I were adjusted for body mass index, smoking status, physical activity, 
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self-reported cardiovascular disease and diabetes. The risk estimates were similar to the sex-
adjusted model, and suggested that confounding by these variables did not explain the 
increased VTE risk in the cancer cohort.  
In paper IV, where we investigated the role of pre-cancer platelet count on the risk of 
VTE, we also observed a positive association between platelet count and cancer stage. Since 
advanced cancer is an acknowledged risk-factor for VTE, the association between pre-cancer 
platelet count and VTE was potentially confounded by higher cancer stage among those with 
high platelet count at baseline. However, including cancer stage in a multivariable model did 
not attenuate the risk estimate, and we inferred that the increased risk of VTE by pre-cancer 
platelet count was not mediated through higher cancer stage.  
To ensure that observed associations are not mediated by dissimilar distribution of 
other risk factors, potential confounders must always be considered in observational studies. 
However, it cannot necessarily be assumed that confounding has been eliminated after 
adjustment for recognized confounders. Residual confounding due to large within-strata 
variations or poor assessment of the confounding variables as well as the presence of 
unrecognized confounders can usually not be ruled out. The gold standard for establishing 
causal relationships are experimental studies where the exposure of interest is randomly 
assigned to study participants, i.e. randomized clinical trials (RCT). However, although the 
role of recognized and unrecognized confounders is diminished in RCTs, confounding may 
still be present due to chance. 
Age is an important confounder in epidemiologic research of many diseases and VTE 
is no exception. The widely used time-scale in Cox regression (Figure 3a) is the time-on-study 
scale, were at-risk subjects at event-time t are those who have not experienced an event or 
been censored before t. However, it has been argued that using age as timescale in the 
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regression analyses is a more proper way of eliminating confounding by age than the 
standard age adjustment in a multivariable model (Figure 3b) (245, 246). 
 
Figure 3. Different time-scales in Cox regression 
(a) Time-on-study time-scale  
 
 




Instead of comparing those who are still in study at time t (counted from the date of 
inclusion), it may be more reasonable to compare the participants who have not 
experienced an event or been censored by age a. The main argument is that there probably 
is a greater variability with respect to the outcome-risk between subjects of different ages, 
than between subjects who have been under observation for different amount of time.  Age 
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as time-scale was applied in papers I and II. This method also allowed for a dynamic and 
more accurate allocation to the age-strata, since subjects were able to switch age-category 
as they aged throughout follow-up.  
When the effect of a risk factor on an outcome varies across another variable which 
is not the exposure of interest, this second variable is known as an effect modifier, and 
means that statistical interaction is present. As opposed to confounding, where the crude 
effect will be weakened or strengthened across all strata of the confounding variable, 
interaction will lead to variation in the risk estimates across the strata (247). Presence of 
statistical interaction can be evaluated on an additive (i.e. absolute risk difference) or 
multiplicative (i.e. relative risk difference) scale, and must be specified as they may reach 
diverging conclusions (248). This was observed in the first two papers of this thesis. In paper 
I, the relative risk of VTE by cancer showed large variation across age-groups (range from 26-
fold to 3-fold increased risk), and suggested that higher age negatively modified the effect of 
cancer on the risk of VTE on a multiplicative scale. Although this is not surprising given the 
large discrepancy in the background risk, it follows that an overall relative risk estimate is 
not applicable to all age-groups, and is especially inaccurate for those aged far from the 
mean. The risk difference on the other hand was quite similar across age-groups, and 
implied that age was not an, or even a slightly positive, effect modifier of the effect of cancer 
on the risk of VTE on an additive scale.  
Another example of interaction was observed in paper III and IV. The leukocyte and 
platelet counts were only associated with VTE among subjects who developed cancer, and 
not among the cancer-free, i.e. the parameters showed statistically different effect in the 
two strata of cancer exposure. This specific form of interaction is termed a qualitative 
  
  58 
 
interaction, as opposed to quantitative interactions where the association is present but 
varies in strength across strata of the interacting variable (247).  
In contrast to statistical interactions, there are no formal statistical tests for biological 
interactions. However, departure from additivity of individual effects may imply that risk 
factors interact with each other on a biological level. In paper IV, by use of Rothman’s 
synergy index (249), we observed that the risk of VTE in subjects with high platelet- and 
leukocyte counts exceeded the expected combined effect of the two parameters. This effect 
was described as synergistic.  
 
5.1.4 Bias 
Bias is the term for systematic errors in epidemiologic research that is related to the 
study design or conduct (247). Bias may be introduced during the selection of study 
participants or during measurement of exposures, confounders or the study outcome. The 
two main categories are selection bias and information bias, but overlap exists. Selection 
bias occurs when exposure or outcome status of an individual influence the probability of 
participating in the study. In case-control studies, selection bias occurs when participation 
status is related to the exposure, and when this association is more pronounced in either 
cases or controls. In cohort studies, the relationship between exposure and outcome must 
be different among those who participate and those who do not participate in the study. 
Thus, selection bias may be important to consider in a case-control study, but rarely leads to 
erroneous associations in prospective studies. However, when a cohort study unintentionally 
consist of selected subjects, absolute effect measures (i.e. incidence rates, cumulative risks 
and attributable proportions) may not be representative of the source population.  
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Information bias is introduced when study participants are placed in the wrong 
exposure or outcome category, known as misclassification. Non-differential misclassification 
is common in prospective studies, and means that misclassification is equally distributed 
among cases and non-cases. Non-differential misclassification dilutes the true associations 
and may result in type II error (250). When the chance of exposure misclassification is 
affected by the outcome status, the misclassification is characterized as differential. 
Differential misclassification may lead to under- or over-estimation of effects and can 
thereby cause type I and type II errors. A classic example of differential misclassification is 
the recall bias in case-control studies, where cases more than controls are prone to over- or 
underestimate previous exposures, or vice versa. Misclassification of confounding variables 
in a study leads to poor control for confounding, potentially causing residual confounding 
(247, 250).  
The exposure status may be related to the medical surveillance of study participants 
and thereby influence the detection of the outcome, and is termed medical surveillance bias 
or detection bias. This bias is often present when the exposure is a disease (such as diabetes 
or cancer) or a treatment (such as oral contraceptives) and the outcome is not systematically 
assessed (247). Since malignancy is a well-known risk factor for VTE and most cancer 
patients see doctors frequently, diagnostic work-up for VTE is probably performed more 
often among oncology patients than for other patient groups. Thus, detection bias should be 
kept in mind when evaluating the effect of cancer on the risk of VTE. In cohort studies, 
detection bias is categorized as a type of information bias. In case control studies the issue 
leads to selection bias. Regardless of study design, detection bias typically causes over-
estimation of the effect.  
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5.1.5 Missing data and loss to follow-up 
Missing data is often encountered in observational studies. There are several 
methods for handling missing values ranging from simple deletions to sophisticated 
imputation techniques (251). The selected approach depends on the volume of missing data 
and the missing data mechanism. These mechanisms generally fall under three categories: 
missing at random (MAR), missing completely at random (MCAR) and not missing at random 
(NMAR). When missing status is independent of the value itself, but related to other 
variables in the data set, such as age or sex, the mechanism is termed MAR. NMAR denotes 
that certain values for the variable itself are more likely to be missing, for instance when 
weight status is more often missing among obese subjects. Conversely, values that are MCAR 
are not related to the variable itself nor other variables in the data set, and may result from 
questionnaires lost in the mail or plotting errors performed by the researcher (252).    
None of the main exposures in this thesis were self-reported (i.e. cancer, WBC- and 
platelet count) and missing values, assumed to be MAR or MCAR, were managed by pairwise 
and listwise deletions (252). Pairwise deletions were performed in papers III and IV, where 
subjects with missing values for the respective exposures (i.e. leukocyte- and platelet count) 
were deleted from the dataset (3-6 %), whereas subjects with missing data for other 
covariates only were excluded from the multivariable analyses. In paper II based on the STAC 
cohort, the proportion of missing data was high for certain self-reported covariates, and 
missing was more common among elderly (i.e. MAR). Initial pairwise deletions where 
subjects with missing values for covariates were excluded from the multivariate analyses 
only, provided higher HR compared to the age-and sex adjusted model. However, this was 
merely an effect of age-reduction. Thus, to ensure that the same subjects were included in 
the different regression models, listwise deletions were performed in paper II, meaning that 
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subjects with missing values for any of the covariates in the multivariable model were 
excluded from all analyses (also termed complete case analysis). A disadvantage of both 
listwise and pairwise deletions are reduced power with a higher probability of type II error 
(251).  
Loss to follow-up in prospective studies is usually handled by censoring. An 
assumption to censored survival time is that these observations have the same risk of the 
event of interest as those who remain in the study (i.e. non-informative censoring). Thus, 
censoring is a reasonable approach when subjects are lost to follow-up due to migration. 
However, even though death from other causes necessarily prevents any future 
development of the study outcome (when the outcome is not all-cause mortality), death is 
often handled as a censored observation. It has been suggested that death from other 
causes than the disease of interest should be considered a competing event, after which 
subjects are no longer at risk (253). In study populations with low mortality such as 
population-based cohort studies, regular Kaplan-Meier survival analysis and the competing 
risk method provide similar results. In cancer- and thrombosis studies however, where a 
large proportion of the exposed population dies within the study period, there may be a 
considerable difference between censoring and competing risk analysis (i.e. overestimation 
of VTE risk when death is handled by censoring). Graphically the Kaplan-Meier- (survival) and 
the failure- (1-survival) curves cross and add up to > 1 (254). By use of the method proposed 
by Fine and Gray (255), death was considered a competing event to VTE in paper I. As 
expected the risk estimates were attenuated, and were most attenuated among the elderly 
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5.1.6 Data quality 
The main exposure throughout this thesis was a diagnosis of cancer obtained from 
the Danish or Norwegian cancer registries. Several measures have been used to assess the 
accuracy and completeness of the registries, including the share of microscopically 
confirmed diagnoses, the number of sources per case, the proportion of cases from death 
certificates only (DCO), and the number of cases with an unknown primary site or cancer 
stage. Morphological verification is warranted and has improved over the years. In Denmark 
the proportion of microscopically confirmed diagnoses increased from 55 % in 1943 to 93% 
in 1992, whereas the proportion of DCO cases decreased from 19 % to 0.7% during the same 
period (256). Correspondingly, 94 % of the cases in the Cancer Registry of Norway (CRN) 
were confirmed by microscopy in 2001-2005 (233). In this period, the average number of 
reporting sources per case was 3.2 in the CRN. Reporting from multiple sources can be used 
to assess the probability of missed cases by the capture-recapture method, either by 
assuming that the sources are independent or by taking dependence between sources into 
consideration (257, 258). The latter was performed by Larsen and colleagues to assess the 
completeness of the CRN (259). Weak, but positive dependencies were noted between 
clinical notifications and death certificates and clinical notifications and pathologists, and a 
negative dependence was observed between death certificates and pathologist. The authors 
estimated that 1.2 % of cancer diagnoses in Norway go undetected suggesting a 
completeness of 98.8%. 
The VTE events included in the Tromsø Study were detected from the hospital 
discharge diagnosis registry, the radiology procedure registry and the autopsy registry. Both 
hospitalized and outpatient cases were registered, meaning that cases diagnosed during 
travel would be captured if the patient subsequently were followed at the hospital 
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outpatient clinic. The careful evaluation of each case by access to the patient’s medical 
record limited the inclusion of false positive cases. Thus, we have reason to believe that the 
VTE registry in the Tromsø cohort has high completeness and validity.  
VTE events in HUNT and DCH applied in paper II were also identified from more than 
one source and validated by objective criteria (13, 128). However, as indicated by previous 
publications (13, 14, 120), lower age-specific rates of VTE were noted in these cohorts 
compared to the Tromsø Study. Possible reasons for the lower rates include fewer sources of 
information (i.e. two not three for each registry), different coding routines and perhaps 
easier access to hospitals outside the study area, leading to missed cases. Theoretically, VTE 
may also be more common in the northern Norway.  
  
5.1.7 External validity 
If the findings are internally valid, i.e. not caused by chance, bias or confounding, the 
next step would be to evaluate the external validity or generalizability. These concepts 
denote that the findings are applicable to populations other than the population where the 
association was investigated. The Tromsø Study is a population-based study intended to 
reflect the general adult population in North Norway. All inhabitants of the municipality 
aged more than 24 years were invited to the fourth survey, and the participation rate was 
high (77 % of the eligible population). A lower participation rate was noted for men 
compared to women, as well as in subjects younger than 30 years and in those > 80 years 
(231). The participation rate in the Diet Cancer Health study in Denmark (Paper II) was lower 
than in Tromsø IV and HUNT2, and only 37 % of women and 34 % of men participated in the 
study. Comparison of socioeconomic factors obtained by central registries revealed large 
variations between participants and non-participants (260). Predictors of participation were 
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higher education, occupational status, housing conditions and marital status, where single 
men had the lowest participation rate.  
Cancer patients in this thesis were health survey participants, and it can therefore be 
argued that the cancer cohort was more health-conscious than cancer-patients as a whole. 
Participants may for instance visit doctors more frequently and have an early diagnosis, and 
thereby have a lower risk of VTE. If the effect of cancer on VTE is modified by factors that are 
unevenly distributed among participants and non-participants, such as smoking habits or 
physical activity, the risk estimates may not be extrapolated to the general population. 
However, this is a highly theoretical selection bias, and is unlikely to have had any major 
impact on the results.  
The relative distribution of cancer sites in papers I and II is in coherence with reports 
from the Nordic cancer registries (233, 261), and supports that the cancer cohorts applied in 
this thesis are representative for cancer in the general population. The benefit of such 
cohorts is the high degree of generalizability of the risk estimates. From a community 
perspective, populations representative for cancer patients as a whole are crucial to assess 
the overall significance of the disease in public health, which cannot be extrapolated from 
studies of high-risk patients. However, the studies do not include children, and is therefore 
not applicable to the risk of VTE amongst children with cancer. Furthermore, the vast 
majority of the population was of Caucasian ethnicity, thus the results may only be 
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5.2  Discussion of main results 
5.2.1 Risk of cancer-associated VTE in the general population (Papers I and II)  
In papers I and II we found crude rates of cancer-associated VTE of 9-13 per 1000 
person-years, and a 5-fold increased risk in comparison to the cancer-free population. Both 
the absolute and relative measures are in reasonable agreement with previous studies 
(Table 1). In a recent publication more than 80 000 cancer patients were identified from the 
UK cancer registry, and VTE rates were obtained by linkage to the nationwide discharge 
diagnosis registry and primary care registry. The crude rate of VTE among cancer patients 
was 14 per 1000 person-years, and the relative risk was 4.7 (49). A meta-analysis from 2012 
also supports our findings (73). Based on the patient composition in the respective cohorts, 
the authors categorized relevant studies as average- or high-risk studies. Three general 
cancer cohorts similar to our own were categorized as average risk studies, and the overall 
VTE rate for this category was 13 per 1000 person-years. However, it should be kept in mind 
that the duration of follow-up was inconsistent between the studies, and the heterogeneity 
of the results is probably more pronounced than implied by the average incidence rate.  
In comparison to previous studies and Paper I, the rate of cancer-associated VTE in 
the STAC cohort was lower than anticipated (IR 8.6 per 1000 PY) (Paper II). However, the 
cumulative risks at cut-offs up to 2 years after the diagnosis were not lower than previously 
reported (44, 45, 49). We therefore suggested that the overall lower rates were due to the 
long duration of follow-up in the STAC study compared to previous studies. As for the 
discrepancies within the STAC cohort, it appears that the Tromsø study exhibited somewhat 
higher rates than previously reported, rather than that the rates in the other two studies 
were particularly low. 
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We were not able to determine any important confounders of the association 
between cancer and VTE. Although there were some differences across baseline variables in 
cancer and non-cancer subjects, the HR for VTE by cancer was not attenuated by adjustment 
for these potential confounders. However, in paper I smoking was initially adjusted for by 
including a dichotomized variable (daily smoking yes or no) in the multivariable Cox-model, 
and it was suggested that residual confounding by smoking quantity could be present. 
Additional adjustment for pack-years for current and former smokers did not attenuate the 
risk estimate. In paper II, smoking was considered by including an ordinal variable 
(categories were never, former, < 15 cigarettes daily, 15-25 cigarettes daily and ≥ 25 
cigarettes daily). Although the difference between these category intervals might not have 
been constant, the variable probably accounted for differences between smoking habits in 
cancer- and non-cancer subjects more accurately than a dichotomized variable. Either way, 
smoking did not appear to be a confounder of the association between cancer and VTE.  
Additional risk factors among those who developed cancer may have been unevenly 
distributed throughout follow-up. For instance, many of the subjects who developed lung 
cancer probably also had chronic obstructive pulmonary disease (262). Other medical 
conditions such as heart failure, diabetes and renal disease may have been more common 
among those who developed cancer and are potential confounders. We did not have 
information about comorbidities during follow-up, and could not take this into 
consideration. Residual confounding by these factors would lead to over-estimation of the 
association between cancer and VTE. In the Danish registry study (34) comorbidity data from 
the Danish National Registry of Patients was included in the multivariable HR model, and 
provided an adjusted relative risk (HR) by cancer of 4.7. However, the authors did not report 
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the unadjusted risk estimates, and the potential role of these comorbidities cannot be read 
from the paper (34).   
In the papers of this thesis, the stability of the risk estimates in multivariable models 
where baseline confounders were included, along with the clear temporal relation between 
the cancer diagnosis and the VTE events, suggest that the association is not heavily 
confounded.  
 An unconfounded association is necessary to obtain meaningful attributable 
proportions from incidence rates. The attributable proportions due to cancer in papers I and 
II (i.e. 23 % and 20 %, respectively) were based on crude rates in the respective populations 
and do not take confounding factors or interaction into consideration (263). Although no 
important confounders were identified in our studies, residual cofounding by unrecognized 
factors or unavailable data cannot be ruled out. Thus, the external validity of these estimates 
relies not only on a similar frequency of the exposure, but also on similar distribution of 
potential confounders and effect modifiers. Furthermore, if one wanted to predict the 
frequency of VTE if cancer was eliminated from the population (as is often attempted for 
modifiable risk factors), the total amount of person-time at risk of VTE would presumably 
increase, which might in fact result in a higher absolute number of cases in the population 
(264). Thus, attributable fractions cannot simply be understood as a preventable share of 
events a population. Nonetheless, with these limitations in mind, attributable proportions 
are useful to easily illustrate the relative importance of a risk factor at population level.  The 
attributable proportions presented in this thesis confirm that cancer is one of the most 
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5.2.2  Time since diagnosis, cancer sites and risk of VTE (Paper II) 
 In paper II we conclude that the strongest predictor for VTE in patients with cancer is 
the proximity to cancer diagnosis. Altogether, more than 50 % of the cancer-related VTE 
events occurred in the one-year period between 6 months before and 6 months after the 
cancer diagnosis. In the 6 months before cancer, subjects exhibited a 7-fold increased risk of 
VTE compared to the cancer-free population. During the first 6 months after manifest 
disease patients had a 17-fold increased risk of VTE, which rapidly declined to a 5-fold 
increased risk within the following 6 months. The elevated risk prior to diagnosis underpins a 
direct impact of malignancy on the hemostatic system previously described in this thesis.  
The pronounced increase in the initial 6 months is probably explained by iatrogenic risk 
factors and comorbidities. This notion is supported by the high frequency of other provoking 
factors in patients with cancer-related VTE observed in paper I, where additional provoking 
factors including recent surgery, medical illness and central venous catheters, were noted in 
almost 50 % of those with cancer-related VTE. Notably, information about chemotherapy 
was not registered among provoking factors, suggesting that the true proportion with 
concomitant risk factors was substantially higher than 50 %.  
The cancers that accounted for the largest proportions of the cancer-related VTE 
events were lung-, colorectal- and prostate cancers (18 %, 13 % and 9 %, respectively), 
whereas rare cancers like pancreatic and brain cancers each explained less than 5 % of the 
cancer-associated VTEs. To the best of our knowledge cancer-specific attributable 
proportions has not previously been estimated. However, the proportions presented in 
paper II are reasonable considering the incidence of these cancers along with the site-
specific risk of thrombosis.  
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As previously demonstrated (34, 45, 49, 265), there were large variations in the risk 
of VTE across cancer sites when the entire follow-up was applied. The cancer sites that 
exhibited the highest relative risk during the study period were pancreas, lung, brain, kidney 
and ovaries. In addition, patients with stomach cancer had a high absolute risk of VTE. 
However, as already shown in previous publications (34, 44, 45), nearly all sites investigated 
in paper II provided high risks of VTE in the initial 6 to 12 months after the cancer diagnosis. 
As discussed in the manuscript, site-specific variations in VTE risk demonstrated during long-
term follow-up may be partly explained by diverging degrees of exposure misclassification.  
For cancers with high mortality, such as pancreatic cancer, there was probably only a small 
proportion of patients who attained remission of the disease. Thus, the exposure status (i.e. 
cancer/non-cancer) presumably had high validity throughout the study period. Conversely, 
for cancers with better prognosis, a significant proportion of the person-time may have been 
accrued from cured individuals. Attenuated risk estimates due to misclassification and 
regression dilution bias can therefore not be ruled out, and would presumably be more 
pronounced for cancers with low mortality.  
 
5.2.3 Age as risk factor for cancer-associated VTE (Paper I+II) 
Guidelines in clinical practice are often age-restricted. This may be founded on age-
dependent complication rates, utility measures (such as quality-adjusted life years) or risk of 
incident disease. High age is often included in VTE prediction models (226, 228, 229) based 
on the higher risk of incident VTE in the elderly. To date, there are no RAMs specifically 
developed for hospitalized oncology patients, and subjects with cancer are subjected to the 
RAMs for hospitalized patients overall.  
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 Papers I and II present age-specific incidence rates and relative risks of VTE in cancer 
patients. In the Tromsø Study (Paper I), the incidence rate among cancer patients showed a 
clear gradient across the three age-categories with doubled rate in those aged ≥ 70 years 
compared to those younger than 50 years (7 and 15 per 1000 person-years, respectively). As 
expected from the low background risk in young subjects, the HR declined with increasing 
age.  
The high number of participants in the merged cohort applied in paper II allowed for 
subgroup analyses, and we were able to calculate the site-specific impact of higher age. 
Interestingly, the effect of high age was small or absent in the groups of high-risk cancers 
during the first year after the diagnosis. Thus, for decisions on thromboprophylaxis among 
cancer patients, which primarily are warranted in this period, our results imply that high age 
should not be emphasized as an independent risk factor. Presumably, the risk of bleeding 
complications is also higher among elderly patients (266). Taken together, it appears unlikely 
that the risk-benefit ratio of prophylaxis is more beneficial among elderly cancer patients. 
The main question in Paper I was whether cancer could explain the increased VTE risk 
in the elderly, and the answer is both yes and no. From calculations of attributable 
proportions in age groups, we concluded that cancer was not a major contributor to the 
increased risk of VTE by advancing age. The conclusion was based on the decline in 
attributable risk (PAR%) from 27 % in middle-aged to 18 % in elderly, which implied that 
other risk factors emerged or increased their influence more than cancer with ageing. 
However, cancer provided a higher number of excess cases among elderly, and thereby 
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5.2.4 White blood cell count and cancer-associated VTE (Paper III) 
Total white blood cell count is a frequently used laboratory parameter in many 
clinical situations. Acute elevation of circulating leukocytes is a sensitive marker of infection 
and inflammatory diseases, and can usually be detected before other inflammation-markers 
such as C-reactive protein (CRP). The inter-individual variation of the normal white blood cell 
count is significant with a reference range of 4-11 x 109cells/L and is influenced by genetic 
and environmental factors (267, 268). The WBC count in healthy humans is mainly 
determined by the number of circulating neutrophils. Neutrophils are short-lived 
granulocytic blood cells (7-10 h in the circulation) important in the innate immune response 
towards bacterial infections. High levels of WBCs and neutrophils have been associated with 
all-cause mortality, cardiovascular mortality and cancer-associated mortality (269-272).  
Since low-grade inflammation is a recognized risk-factor for myocardial infarction as well as 
for cancer development, it is not known whether these relationships are causative or due to 
a pro-inflammatory state in subjects with high WBC count.  
Leukocytosis (WBC count ≥ 11 x 109 cells/L) has recently been associated with VTE in 
several studies of ambulatory cancer patients (115, 202, 273, 274). In the present study, we 
observed an increased risk of VTE among subjects with high baseline WBC count who 
subsequently developed cancer, but not among those who remained cancer free.  
It may be hypothesized that the positive association in the cancer cohort is due to a 
systemic inflammation, rather than the leukocytes per se. However, as opposed to 
atherosclerosis and cancer, the role of low-grade inflammation in the pathogenesis of VTE 
has been a subject of discussion. Case-control studies have demonstrated an association 
between inflammation markers and VTE in the acute phase, and a few prospective studies 
have found positive associations between CRP-levels and subsequent VTE (275, 276). Other 
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prospective studies have questioned these findings. CRP, fibrinogen and white blood cell 
count was not associated with VTE in the LITE study (277), pro-inflammatory cytokines did 
not provide excess risk of VTE in a nested case-cohort design of the HUNT study (278), and  
baseline high-sensitivity CRP level was not associated with future VTE in the Tromsø Study 
(279). In the CATS cohort, CRP was associated with an increased risk of VTE after one year, 
but the effect disappeared in the multivariable model adjusted for age, BMI, surgery, 
chemotherapy, radiotherapy and p-selectin (280). Altogether, the conflicting results indicate 
that low-grade inflammation is not an important contributor to development of VTE.  
Conversely, acute inflammation is a well-established risk factor for venous 
thrombosis, and a high risk of VTE has been observed in inflammatory disorders (281-284) 
and acute infections (170-172). In the present study we did not have information about 
comorbidities such as autoimmune or infectious diseases. However, if the association was 
explained by underlying comorbidity in patients with high leukocyte count, a positive risk 
estimate would be expected also in the cancer-free cohort.  
Leukocytes are recognized cellular components of venous thrombi. In a mouse model 
of DVT based on venous stasis, von Bruhl and colleagues demonstrated that leukocytes 
adhered to the endothelium early in the DVT formation, and that the majority of these 
leukocytes were neutrophils (285). They demonstrated that neutropenic mice developed 
significantly smaller thrombi, and further observed that TF played a key role in coagulation 
following depressed flow, and that the TF was derived from myeloid cells, not the vessel 
wall. Apart from TF provided by monocytes, the neutrophils contributed to coagulation by 
formation of NETs.  
Since the baseline leukocyte count to a larger extent is determined by genetic factors 
and clearly is less influenced by emerging confounders during malignancy, the use of pre-
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cancer WBC counts may be regarded as a proxy for mendelian randomization. By using WBC 
counts that were unbiased by the malignant disease, it can be argued that the present study 
provides reliable evidence for a causal relationship between WBC count and cancer-
associated VTE. Although biological interactions cannot be established based on statistical 
effect modification, this notion is not unlikely. The observation that the association between 
WBC count and VTE was restricted to cancer patients supports that cancer-associated 
factors (i.e. the malignant microenvironment, chemotherapy, surgery, acute infections etc.) 
interact with leukocytes in a way that makes the number of circulating leukocytes to a 
determinant of venous thrombosis.  
A recent publication by Demers and colleagues reported that the neutrophils in mice 
with solid or hematological cancers released more NETs upon stimulation than neutrophils in 
cancer free mice, and suggested that this pathway could be important in cancer-associated 
thrombosis (286). Chemotherapy has also been shown to promote the release of cell-free 
DNA (166). Further investigation is needed to establish other potential cancer-leukocyte 
interactions that may take part in the pathogenesis of cancer-related VTE.   
 
5.2.5 Platelet count and cancer-associated VTE (Paper IV) 
Blood platelets are crucial components of the hemostatic system and are 
acknowledged contributors in the development of thrombosis. Traditionally, their role in 
thrombus initiation has been emphasized for arterial thrombotic disease, and to a lesser 
extent in venous thrombosis. However, several studies suggest that antiplatelet therapy 
reduce the risk of VTE (287-289), and mean platelet volume (MPV), a marker of platelet 
activation, has previously been associated with VTE in the Tromsø study (290).  
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Elevated platelet count is a common finding in patients with cancer and is associated 
with a poor prognosis in many solid tumors (291, 292).  Thrombocytosis has been found to 
predict VTE in ambulatory cancer patients (112-114), but has not been associated with VTE 
in prospective studies of the general population (125, 290, 293). In accordance, we observed 
that a baseline platelet count above the 80th percentile were associated with increased risk 
of VTE in subjects who developed cancer, but not in those who remained cancer free. The 
finding indicates that elevated platelet count is not only related to VTE as a marker of acute 
inflammation or advanced cancer, but may also play a direct role in development of VTE in 
cancer patients.  
Activation of platelets in subjects with cancer is a potential explanation of the 
observed interaction. In contrast to the fairly limited knowledge about cancer-leukocyte 
interactions, the platelet-cancer interplay is well-established. The phenomenon has been 
termed tumor cell induced platelet aggregation (TCIPA) and has been described in several 
studies (294-296). A number of mechanisms may take part in the process (296). Both P-
selectin and the fibrinogen-receptor GP IIb/IIIa have been noted as important mediators of 
platelet-cancer cell interactions through binding of adhesion molecules on cancer cells (297, 
298). Generation of thrombin, a potent platelet activator, by lung and pancreatic cancer cell 
lines were demonstrated already in the mid-nineties (294, 295), and other platelet agonists 
such as ADP, thromboxane A and MMPs derived from  cancer cells has also been suggested 
as potential mediators of TCIPA (299). In vivo studies have reported high levels of the 
platelet activation marker soluble P-selectin in cancer patients compared to healthy controls 
(300-302) and underpins that platelets are activated in these patients. Moreover, P-selectin 
on the platelet surface is also a mediator of platelet-leukocyte interactions (299) and 
platelets may thereby be important in DVT propagation by recruitment of leukocytes. 
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Other features than the malignant environment itself may also influence platelet 
activation in patients with cancer. In vitro studies have demonstrated that platelet 
aggregation can be induced directly by chemotherapy (167). Further on, thrombocytosis has 
been associated with VTE risk in hospitalized medical patients (303), in trauma patients (304, 
305) and in patients who undergo cancer surgery (178).  An increased risk of VTE has also 
been noted in patients with reactive thrombocytosis during the recovery phase of critical 
illness (306). Thus, there is convincing evidence that elevated platelet count is associated 
with the risk of future VTE in situations where the circulating platelets tend to be activated. 
In line with this notion, a protective effect of aspirin has been observed in high risk patients 
(287, 307, 308), whereas a trial of healthy women failed to demonstrate an effect (309).  
The platelet count in our study was measured before the cancer diagnosis and it is 
not known how it is related to the platelet count during malignancy. Even though it is 
reasonable to assume that those with a baseline platelet count above the 80th percentile 
would be more prone to thrombocytosis during the period of active cancer, it is possible that 
the risk of VTE is mediated through other pathways. For instance, platelets are an important 
source of vascular endothelial growth factor (310), which is essential in angiogenesis (311, 
312). It has been demonstrated that platelets are important in cancer development and 
metastasis (313). Interestingly, we observed that a platelet count in the upper clinical range 
was associated with a higher risk of distant metastases at the time of cancer diagnosis. Since 
the latter is also related to VTE, the increased risk of VTE in those with high pre-cancer 
platelet count were potentially mediated through a higher risk of metastasis. However, 
adjustment for cancer stage in the multivariable model did not attenuate the risk estimate. 
The latter observation undermines the hypothesis that risk of VTE was mediated primarily 
through more advanced cancers in those with high platelet count.  
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Altogether, mechanistic knowledge about the role of platelets in thrombosis along 
with the predictive properties of thrombocytosis and platelet activation markers noted in 
cancer patients provides solid biological and epidemiological grounds for our findings. Our 
own and other recent observations support a causal role of platelet count in cancer-
associated VTE. Similar to our conclusion with respect to WBC- and neutrophil counts, our 
findings suggest that conditions such as malignancy are mandatory for the platelet count to 
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6 CONCLUSIONS 
 Venous thromboembolism is common in patients with cancer and is diagnosed in 
approximately 3-5 % of all cancer patients. The highest rate was observed in the Tromsø 
Study (Paper I), where the overall incidence of cancer-associated VTE was 13 per 1000 
person-years. The relative risk was substantially higher in the young, whereas the incidence 
was higher in the elderly. The proportion of VTE events in the population that was due to 
cancer (PAR %) altogether was 24 %, and declined from 27% in the middle-aged to 18 % in 
those aged more than 70 years. We therefore concluded that the high risk of VTE in the 
elderly not is mediated through a high frequency of malignancy at high age (Paper I).  
 Paper II had greater power compared to Paper I and we were able to apply more 
narrow age-groups (i.e. 10-year categories), perform site-specific analyses and time-
restricted estimates. The study generally confirmed the findings of paper I, and suggested 
that 20 % of the VTE events were due to cancer. Although the VTE-rates were higher among 
elderly in the long-term follow-up, the rates between age-groups did not differ much in the 
first year after diagnosis. Since more than 50 % of the VTE events occurred within the 6 
months before and 6 months after manifest cancer, proximity to the cancer diagnosis 
appeared to be the strongest risk factor for cancer-related VTE.  There were large site-
specific differences when all years of follow-up was applied in the calculations (e.g. high risk 
for pancreatic, lung- and brain cancers), but was less pronounced when analyses were 
restricted to the initial period after diagnosis (e.g. most cancers exhibited an initial high risk 
of VTE). We therefore suggest that the majority of cancers, with exception of breast and 
prostate cancer, are associated with a high initial risk of venous thrombosis. 
 In paper III and IV we found that high white blood cell count and platelet count (> 
80th percentile) measured before development of cancer were risk factors for cancer-related 
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VTE. Increased levels of in these parameters have previously been identified as risk factors 
for VTE in cancer patients. Since the present measurements were unbiased by the severity of 
the malignant disease and associated comorbidities, our findings adds to current knowledge 
by suggesting a causal relationship between WBC- and platelet count and development of 
VTE in cancer patients. In agreement with previous studies, WBC- and platelet count were 
not associated with VTE in those who remained free of cancer throughout follow-up.  
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7  IMPLICATIONS OF RESULTS AND FUTURE PERSPECTIVES 
Throughout this thesis we have demonstrated that most effect measures of the 
association between cancer and VTE are ambiguous and that interpretation and 
comparisons not are straight forward. Due to the pronounced decline in risk after diagnosis, 
both site-specific mortality and the duration of follow-up set by the researcher has 
implications on hazard ratios and incidence rates. Although sophisticated statistical methods 
may provide more accurate results, they may also become incomprehensible to the reader. 
Simple cumulative risks (i.e. the number of events divided by the number of subjects at risk) 
should not be underestimated as a useful effect measure in cancer-and thrombosis studies.  
Close to 30 000 subjects are diagnosed with cancer each year in Norway (233) and 
make cancer-associated VTE an important health concern. In fact, by applying the 1-year 
cumulative risk of VTE demonstrated in the STAC cohort (i.e. 1.6 % in cancer patients), we 
estimate that approximately 500 subjects newly diagnosed with cancer will suffer from VTE 
in Norway each year. Similarly, given that the risk does not vary substantially between 
ethnicities, the world annual incidence of 14 million cancer diagnoses (314) suggests that 
more than 200 000 cancer-patients develop VTE each year world-wide.  
Despite the high risk of VTE associated with malignant diseases, proper 
administration of prophylaxis during hospitalization has been especially poor in oncology 
patients (315-317). Important risk factors in the general population do not necessarily apply 
to these patients, and risk assessment tools such as the Padua prediction score may thereby 
be inaccurate, for instance by assigning higher scores to elderly subjects. To improve the 
targeted prophylaxis in cancer patients, we suggest that future studies continue to define 
risk prediction models for cancer outpatients and hospitalized oncology patients. To increase 
the awareness of VTE in oncology, the importance of thromboembolic complications should 
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perhaps be communicated in clinical departments where high risk patients are admitted, 
including divisions for lung-, gastroenterological- and neurological cancer patients.  
The strong temporal relationship between the diagnosis of cancer and the VTE events 
points towards a significant contribution of treatment-related factors in the pathogenesis of 
cancer-related VTE. However, studies that have evaluated the risk of VTE by different 
treatment modalities are based on initial treatment reported to cancer registries (34, 44). To 
ensure appropriate timing of prophylactic treatment in patients with various cancers, future 
studies should aim to distinguish between the different treatments, clinical risk factors such 
as performance status as well as cancer biology as underlying causes for the VTE events. A 
case-crossover design might be useful to identify the triggers of VTE in oncology-patients.  
Finally, the emerging knowledge about risk factors and biomarkers now available 
makes identification of patients with the highest risk feasible. However, an arising challenge 
for future trials and clinical practice will be to make decisions on the patients within an 
intermediate risk class. To determine the appropriate risk-level above which prevention is 
beneficial, more knowledge about the safety of prophylactic anticoagulation in various 
clinical settings in oncology is needed. Due to possible variations in bleeding rates within 
cancer sites and age-groups, age- and site-specific complication rates and corresponding 
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       Appendix 
 
      The Health Survey is coming to Tromsø. 
This leaflet will tell you when and where. You will 
also find information about the survey in the enclosed 
brochure. 
     We would like you to fill in the form overleaf and 
take it with you to the examination. 
    The more people take part in the survey, the more 
valuable its results will be. We hope, therefore, that 
you will be able to come. Attend even if you feel 
healthy, if you are currently receiving medical 
treatment, or if you have had your cholesterol and 
blood pressure measured recently. 
Yours sincerely, 
Municipal Health Authorities 
Faculty of Medicine - University of Tromsø 
National Health Screening Service 
 Electoral ward No. Municipality  Social security No.Date of birth     
HEALTH SURVEY 
Invitation                                                                  
   
Welcome to the Tromsø Health Survey!                 
“THIS IS YOUR
       CHANCE”
“THIS IS A REAL 
OPPORTUNITY- TAKE IT!”
 What is your current state of health? 
 Do you have, or have you had: 
 Do you use blood pressure lowering drugs? 
Have you during the last year suffered from pains 
and/or stiffness in muscles and joints that have 
lasted continuously for at least 3 months? 
 Have you in the last two weeks felt: 
How has your physical activity in leisure time been during this 
last year? 
How many cups of coffee do you drink daily?      
Are you a teetotaller?                        
How many times a month do you normally drink      
alcohol?        
 Did any of the adults at home smoke while 
you were growing up? 
 Do you currently, or did you previously, live together
 with daily  smokers after your 20th birthday? 
 If "YES", for how many years in all? .............
 How many hours a day do you normally spend 
in smoke-filled rooms? .....
Do you yourself smoke: 
If you previously smoked daily, how long 
is it since you quit?.........................................
If you currently smoke, or have smoked     
previously:       
How many glasses of beer, wine or spirits do you        
normally drink in a fortnight?
What type of margarine or butter do you usually use on     
bread?     
What is the highest level of education you have completed?
What is your current work situation?           
How many hours of paid work do you have per 
week? 
Do you receive any of the following benefits? 
Have one or more of your parents or      
siblings  had a heart attack or had
angina (heart cramp)? ..............................
          
    
Tick one box only. 
Poor  




Angina pectoris (heart cramp)   













 Put 0 if you do not spend time in smoke-filled rooms. 
Cigarettes daily?    
Cigars/ cigarillos daily?    
A pipe daily?
How many cigarettes do you or did you  
usually smoke per day?    
How old were you when you began  
daily smoking?
How many years in all have you smoked  
daily?   
Think of your weekly average for the year. 
Time spent going to work counts as leisure time. 
Light activity (not       
sweating/out of breath)  
Hard activity (sweating/
out of breath) ..........
Coarsely ground coffee for brewing
Other coffee
Hours per week
None    Less than 1 1-2   3 or more
Put 0 if you do not drink coffee daily.     
Put 0 if less than once a month.  .....
Do not count low-alcohol beer. 
Tick one box only. 
Do not count low-alcohol beer. 
Put 0 if less than once a month. 
Don't use butter/margarine 
Butter .............
Hard margarine 
Soft margarine ....... 
Butter/margarine mixtures
Light margarine  
7-10 years primary/secondary school,          
modern secondary school
Technical school, middle school, vocational   
school, 1-2 years senior high school 
High school diploma                                       
(3-4 years)........................




Unemployed, on leave without payment
Sickness benefit (sick leave) 






   Cups      
   Cups      
    Times  
Glasses Glasses Glasses 
Beer Wine 
 
  Spirits    
 No. of     
hours  
   Years   
cigarettes
Age
        years
   Years   
   Years   
   Hours   
 Age first       






Yes No Don't know
No  A little
  
   A lot 
  Very 
  much




EDUCATION/WORK            SMOKING






    The main aim of the Tromsø Study is to improve our 
knowledge about cardiovascular diseases in order to aid 
prevention. The survey is also intended to improve our 
knowledge of cancer and other general conditions, such as 
allergies, muscle pains and mental conditions.  We would 
therefore like you to answer some questions about factors 
that may be relevant for your risk of getting these and other 
illnesses. 
   This form is a part of the Health Survey, which has been 
approved by the Norwegian Data Inspectorate and the 
Regional Board of Research Ethics. The answers will only 
be used for research purposes and will be treated in strict 
confidence. The information you give us may later be stored 
along with information from other public health registers in 
accordance with the rules laid down by the Data Inspectorate 
and the Regional Board of Research Ethics. 
  If you are in doubt about what to answer, tick the box that 
you feel fits best. 
  The completed form should be sent to us in the enclosed 
pre-paid envelope. 
Thank you in advance for helping us. 
Yours sincerely, 
Faculty of Medicine  National Health 
University of Tromsø Screening Service
 
If you do not wish to answer the questionnaire, tick the 
box below and return the form. Then you will not receive 
reminders. 
I do not wish to answer the questionnaire ..................................
 Date for filling in this form:................................
 Day  Month  Year
In which Norwegian municipality did you live  at the age of 1 year? 
If you did not live in Norway, give country of residence instead of municipality.
How was your family's financial situation during your 
childhood? 
Very good ..............................................................
How many of the first three years of your life   
How many of the first 15 years of your life                  
 Who do you live with?                
Good ........................................................................
Difficult .....................................................................
Very difficult  .............................................................
 - did you live in a town/city? .......................................
 - did your family have a cat or dog in the home? .......
 - did you live in a town/city? .......................................





Yes No  
Yes No  
Yes No  
Yes No  
Yes  No   Tick once for each item and give the number .       
 Spouse/partner ............................................
 Other people over 18 years .........................
 People under 18 years ................................
How many of the children attend day care/kindergarten? ....




Terraced /semi-detached house ........................
Other ..................................................................
 How big is your house? ..................................................
 Approximately what year was your house built? ............
 Has your house been insulated after 1970?...............
 Do you live on the lower ground floor/basement? .....
 If "Yes", is the floor laid on concrete? ...................
What is the main source of heat in your home?   
Number   
Electric heating ......................................................
Wood-burning stove .................................................
Central heating system using:                  
Paraffin ...................................................................
Electricity ................................................................
Do you have fitted carpets in the living room? ............
Is there a cat in your home? .......................................
Is there a dog in your home? ......................................
If you have paid or unpaid work, how would you describe   
 your work? 
Mostly sedentary work? .........................................
(e.g. office work, mounting) 
Work that requires a lot of walking? ..........................
(e.g. shop assistant, light industrial work, teaching)  
Work that requires a lot of walking and lifting? ..........
(e.g. postman, nursing, construction) 
Heavy manual work? .................................................
(e.g. forestry, heavy  farm-work, heavy construction) 
Can you decide yourself how your work should be         
organised? 
No, not at all ..........................................................
To a small extent ......................................................
 Who do you live with?   Yes, to a large extent ................................................
Are you on call, do you work shifts or nights?.............
Do you do any of the following jobs (full- or part-time)?




Yes, I decide myself ..................................................
       HOME   
      WORK
CHILDHOOD/YOUTH
The Tromsø Health Survey                            
   ILLNESS IN THE FAMILY  
   USE OF HEALTH SERVICES   
YOUR OWN ILLNESSES        SYMPTOMS      
Do you cough about daily for some periods of the year?
Have you ever had: 
Tick one box only for each item. Give your age at the time. 








Have you you ever had, or do you still have: 







Fibromyalgia/fibrositis/chronic pain syndrome .........





Allergy and hypersensitivity: 




Other hypersensitivity (not allergy) ....................
How many times have you had a cold, influenza (flu),
vomiting/diarrhoea, or similar in the last six months? 
Have you had this in the last 14 days?.......................
Tick for the relatives who have or have ever
had any of the following diseases: 
Tick "None" if none of your relatives have had the disease.               
Cerebral stroke or brain haemorrhage








age when they got
diabetes ..................................
If "Yes":     
Is your cough productive ? ..............................
Have you had this kind of cough for as long as
3 months in each of the last two years? ............
Have you had episodes of wheezing in your chest?
If "Yes", has this occurred:      
Tick one box only for each item.     
At night ................................................................
In connection with respiratory infections ..................
In connection with physical exertion ........................
In connection with very cold weather .......................
Have you noticed sudden changes in your pulse 
or heart rhythm in the last year?.................................
How often do you suffer from sleeplessness? 
Never, or just a few times a year .........................
1-2 times a month .....................................................
Approximately once a week ......................................
More than once a week .............................................
If you suffer from sleeplessness, what time       
of the year does it affect you most? 
No particular time of year ...................................
Especially during the polar night .............................
Especially during the midnight sun season .............
Especially in spring and autumn ..............................
Have you in the last year suffered from sleeplessness
to the extent that it has affected your ability to work?...
How often do you suffer from headaches? 
Rarely or never .....................................................
Once or more a month ...............................................
Once or more  a week ...............................................
Daily ...........................................................................
Does the thought of getting a serious illness ever 
worry you? 
Not at all ...............................................................
Only a little ................................................................
Some .........................................................................
Very much .................................................................
How many visits have you made during the past year 
due to your own health or illness:
Tick 0 if you have not had such contact 
To a general practitioner (GP)/Emergency GP ............
To a psychologist or psychiatrist .....................................
To an other medical specialist (not at a hospital) ............
To a hospital out-patient clinic .....................................
Admitted to a hospital ......................................................
To a medical officer at work .............................................
To a physiotherapist ....................................................
To a chiropractor .............................................................
To an acupuncturist .........................................................
To a dentist ..................................................................
To an alternative practitioner (homoeopath, foot zone therapist, etc.) 
To a healer, faith healer, clairvoyant  ..............................
Number of times 
the past year
Yes  No  
Yes  No  
Yes  No  
Yes  No  
Yes  No  
Age    
times     
Mother Father Brother Sister Child None  
Gastric/duodenal ulcer surgery ....................
MEDICATION AND DIETARY SUPPLEMENTS            FOOD HABITS           
       FRIENDS      
Have you for any length of time in the past year used any of the 
following medicines or dietary supplements daily or almost daily? 
Indicate how many months you have used them. 
Put 0 for items you have not used. 
Medicines
Painkillers ............................................................







Dietary supplements            
Iron tablets ...........................................................
Calcium tablets or bonemeal ...................................
Vitamin D supplements ............................................
Other vitamin supplements ..................................
Cod liver oil or fish oil capsules ...............................
Have you in the last 14 days used the following             
medicines  or dietary supplements? 
Tick one box only for each item. 
Medicines            
months
good
friends    
Painkillers           .............................................................
Antipyretic drugs (to reduce fever) ...........................
Migraine drugs .........................................................
Eczema cream/ointment ..........................................
Heart medicines (not blood pressure) ......................




Other drugs for nervous conditions ..........................
Antacids ...............................................................
Gastric ulcer drugs ...................................................
Insulin .......................................................................
Diabetes tablets ........................................................





Calcium tablets or bonemeal ...................................
Vitamin D supplements ............................................
Other vitamin supplements ..................................
Cod liver oil or fish oil capsules ................................
- jam and other sweet spreads .......
confidentially with and who give you help when you need it? 259
Do not count people you live with, 
but do include other relatives!  
How many of these good friends do you have 
contact with at least once a month? .........................
Do you feel you have enough good friends? ...........
How often do you normally take part in organised   
gatherings, e.g. sewing circles, sports clubs, 
political meetings, religious or other associations?     
Never, or just a few times a year .........................
1-2 times a month ....................................................
Approximately once a week .....................................
More than once a week ............................................ Waffles, cakes, etc. ..................
Chocolate .......................................
Sugar-free ("Light") soft drinks .....








- lean fish (e.g. cod)  ....................
- fatty fish (e.g. salmon/redfish)
- sausage/meatloaf/ meatballs .....
Dinner with
- unprocessed meat......................
Breakfast cereal/ oat meal, etc. ...
Boiled or fried egg ........................
Yoghurt ....................................
How many times per week do you normally eat the following foodstuffs? 
How many good friends do you have whom you can talk
What kind of fat is normally used in cooking         
(not on the bread) in your home? 
A catering portion is enough for about
If you use butter or margarine on your bread, how many slices does   
a small catering portion normally cover? By this, we mean the 






Tick one or two boxes! 
The bread I eat is most similar to:
Sleeping pills 
How much (in number of glasses, cups, potatoes or slices) do you   
usually eat or drink daily of the following foodstuffs? 
Tick one box for each foodstuff. 
Full milk (ordinary or curdled) (glasses)
Semi-skimmed milk .........................
(ordinary or curdled) (glasses)
Tea (cups) .......................................
Orange juice (glasses) ....................
Potatoes .....................................
Slices of bread in total 
(incl. crisp-bread) ............................
Slices of bread with 
- fish 
(e.g. mackerel in tomato sauce) .....
- lean meat                    
(e.g. ham) .......................................
- fat meat                       
(e.g. salami) ....................................
- cheese (e.g. Gouda/ Norvegia) .........
- brown cheese ...............................







  Coarse 
brown  
   Crisp 
  bread 
Skimmed milk (ordinary or curdled) (glasses)
Tick a box for all foodstuffs listed. 
slices   
 Less 
 than 1 
 More 
than 6 
  Never 
 Less 
 than 1 
  almost  
daily 










What kind of bread (bought or hom -made) do you usually eat?         
      ALCOHOL
How often do you usually drink   
Never, or just a few times a year .......
1-2 times a month ..............................
About once a week ............................
2-3 times a week ...............................
More or less daily ..............................
Approximately how often during the last year have you consumed 
alcohol corresponding to at least 5 small bottles of beer, a bottle 
of wine, or 1/4 bottle of spirits?            
Not at all the last year ...............................................
A few times ...............................................................
1-2 times a month .....................................................
1-2 times a week ......................................................
3 or more times a week ............................................
For approximately how many years has your alcohol       
consumption been as you described above? ..................
- before age 20 ..................................................
years
   spirits?   wine?beer?
 TO BE ANSWERED BY WOMEN ONLY 
      MENSTRUATION   
      PREGNANCY     
      WEIGHT REDUCTION   
      URINARY INCONTINENCE       
      CONTRACEPTION AND ESTROGEN  
- later .................................................................
If you have lost weight deliberately, about how many                 
kilos have you ever lost at the most? 
- before age 20 ..............................................................
- later .............................................................................
What weight would you be satisfied with 
(your "ideal weight")? ....................................................
How often do you suffer from urinary incontinence?
Never ...................................................................
Not more than once a month ...................................
Two or more times a month .....................................
Once a week or more ..............................................
Your comments:            
Do you use, or have you ever used: 
Oral contraceptive pills (incl. minipill) ...
Hormonal intrauterine device ....................
Estrogen (tablets or patches) ..............
Estrogen (cream or suppositories) ............
If you use oral contraceptive pills, hormonal intrauterine device,                 
or estrogen, what brand do you currently use? 
If you use or have ever used oral contraceptive pills: 
How many years in total have you taken the pill? .....
If you have given birth, how many years did you 
take the pill before your first delivery? .......................
If you have stopped taking the pill: 
       Age when you stopped? .....................................
Thank you for the help! Remember to mail the form today! 
The Tromsø Health Survey 
How old were you when you started                       
menstruating? ................................................................
If you no longer menstruate, how old were
you when you stopped menstruating? ...........................
you ever stopped having menstruation for      
6 months or more? ...................................................
If "Yes", how many times? ..................................
If you still menstruate or are pregnant:                         
What date did your last menstruation period begin?
Do you usually use painkillers to                       
relieve period pains? ............................................
How many children have you given birth to? .............
Are you pregnant at the moment? ....................
Have you during pregnancy had 
high blood pressure and/or proteinuria? ...........
If "Yes", during which pregnancy? 
High blood pressure ....................................
Proteinuria ...................................................
If you have given birth, fill in for each child the year of birth 
and approximately how many months you breastfed the child. 
Child Year of birth:  
About how many times have you deliberately tried to 
lose weight? Write 0 if you never have. 
Apart from pregnancy and after giving birth, have        
Yes  No 
day/month/year
 times  
  No Yes 
years
years
Number of months 
breastfed:
Yes  No 
Yes  No 
 children  
 Don't know  
 Pregnancy
First         Later  
Age when you started to take the pill? ......................
  times  





  times  
 The main aim of the Tromsø Study is to improve our 
knowledge about cardiovascular diseases in order to aid 
prevention. The survey is also intended to improve our 
knowledge of cancer and other general conditions, such as 
allergies, muscle pains and mental conditions. Finally, the 
survey should give knowledge about the older part of the 
population. We would therefore like you to answer the 
questions below. 
    This form is a part of the Health Survey, which has been 
approved by the Norwegian Data Inspectorate and the 
Regional Board of Research Ethics. The answers will only 
be used for research purposes and will be treated in strict 
confidence. The information you give us may later be stored 
along with information from other public health registers in 
accordance with the rules laid down by the Data 
Inspectorate and the Regional Board of Research Ethics. 
     If you are in doubt about what to answer, tick the box that 
you feel fits best. 
     The completed form should be sent to us in the enclosed 
pre-paid envelope. 
Thank you in advance for helping us. 
Yours sincerely, 
Faculty of Medicine National Health 
University of Tromsø Screening Service 
 If you do not wish to answer the questionnaire, tick the box below 
and return the form. Then you will not receive reminders. 
I do not wish to answer the questionnaire ..................................
 Date for filling in this form: ..............................
Day   Month   Year
 Who do you live with?      
 Tick once for each item and give the number.        Yes    No   Number
Spouse/partner ..............................................
Other people over 18 years ...........................
People under 18 years ...................................
 What type of house do you live in? 
Villa/ detached house ....................................
Farm ...................................................................
Flat/apartment ...................................................
Terraced /semi-detached house ......................
Other ...................................................................
How long have you lived in your present home? .............
 Is your home adapted to your needs? .............
 If "No", do you have problems with: 
Living space ...................................................
Variable temperature, 





Other (please specify) ...................................
Spouse/partner Would y  like to move into a retirement home? ..
How will you describe the type of work you had for the last 5-10   
years before you retired? 
Mostly sedentary work? ..........................................
(e.g. office work, mounting)     
Work that requires a lot of walking? .........................
(e.g. shop assistant, housewife, teaching) 
Work that requires a lot of walking and lifting? .......
(e.g. postman, nurse, construction) 
     
Did you do any of the following jobs    
(full-time or part-time)? 




How old were you when you retired? ............................
What kind of pension do you have? 
Basic state pension ..............................................
An additional pension ...........................................





Yes   No 
Years 
years  









How was your family's financial situation during your              
childhood? 
If you did not live in Norway, give country instead of municipality
 
In which Norwegian municipality did you live at the age of 1year?  
CHILDHOOD/YOUTH  
PREVIOUS WORK AND FINANCIAL SITUATION 
   HOME    
Tromsø Health Survey 
for the over 70s 
Heavy manual work .....................................................
(e.g. forestry, heavy farm-work, heavy construction)
Yes   No 
Yes   No 
Yes   No 
Yes   No 
Yes   No 
 No A little 
   ILLNESS IN THE FAMILY       HEALTH AND ILLNESS    
   YOUR OWN ILLNESSES    
    SYMPTOMS      
Tick for the relatives who have or have ever had 
any of the following diseases: 
Has your state of health changed in the last year?
 Yes, it has got worse ..............................................
No, unchanged ...........................................................
Yes, it has got better ..................................................
How do you feel your health is now compared to       
others of your age? 
Much worse .............................................................
A little worse ...............................................................
About the same ..........................................................
A little better ...............................................................
Much better .................................................................
Have you ever had:                
Hip fracture ....................................................
Have you ever had:      Wrist /f rearm fr cture ..................................
Whiplash  .......................................................
Injury requiring  hospital admission ...........
Gastric ulcer  .................................................
Duodenal ulcer  .............................................
Gastric/duodenal ulcer surgery ...................
Have you ever had, or do you have: 
Tick one box only for each item. Give your age at the time. 
If you have had the condition several times, how old were 
you last time? 
Neck surgery ..................................................
Tick one box only for each item. 
Cancer  ......................................................................






Fibromyalgia/fibrositis/chronic pain syndrome ......
Psychological problems for which you have sought help 
Thyroid disease ..........................................................
Liver disease ............................................................







Allergy and hypersensitivity 
Atopic eczema (e.g. childhood eczema) .............
Hand eczema .........................................................
diarrhoea/vomiting or similar in the last 6 months?
Food allergy ...........................................................
Other hypersensitivity (not allergy) ....................
How many times have you had a common cold, influenza (flu), 
times    
Hey fever ............................................................
Have you had this in the last 14 days? .................
Tick "None" if none of your relatives have had the disease.                  
Mother Father Brother Sister Child  None 
Cerebral stroke or brain haemorrhage  









- age when they got
diabetes ..........................................
Do you cough about daily for some periods 
of the year? ..................................................................
If “Yes”:     
Is your cough productive? ................................
Have you had this kind of cough for as long 
as 3 months in each of the last two years? ......
Have you had episodes with wheezing in your chest?
If "Yes", has this occurred:        
Tick one box only for each item. 
At night ....................................................................
In connection with respiratory infections ................
In connection with physical exertion .......................
In connection with very cold weather ...................
Have you noticed sudden changes in your pulse 
or heart rhythm in the last year? ................................
Have you lost weight in the last year? ......................
If “Yes”:   
How many kilograms? ............................................
How often do you suffer from sleeplessness? 
Never, or just a few times a year ...........................
1-2 times a month .......................................................
Approximately once a week .......................................
More than once a week ...............................................
If you suffer from sleeplessness, what time of 
the year does it affect you most? 
No particular time of year ......................................
Especially during the polar night ..............................
Especially during the midnight sun season ............
Especially in spring and autumn ..............................
Do you usually take a nap during the day? ....
Do you feel that you usually get enough sleep? 
Do you suffer from: 
Dizziness .......................................................
Poor memory ....................................................
Lack of energy ..................................................
Constipation .................................................
 Age  
  A lot 
     BODILY FUNCTIONS       
MEDICATION AND DIETARY SUPPLEMENTS
   FAMILY AND FRIENDS   
 USE OF HEALTH SERVICES  
Does the thought of getting a serious illness ever 
worry you?             
Not at all ..................................................................
Only a little ..................................................................
Some ............................................................................
Very much ...................................................................
Can you manage the following everyday 
activities on your own without help from 
others? 
Walking indoors on one level ......................
Walking up/down stairs ....................................
Walking outdoors ..............................................
Walking approx. 500 metres ............................
Going to the toilet .............................................
Washing yourself ..........................................
Taking a bath/shower .......................................
Dressing and undressing .................................
Getting in and out of bed .................................
Eating .................................................................
Cooking ..........................................................
Doing light housework (e.g. washing up) ..........
Doing heavier housework (e.g. cleaning floor) 
Go shopping ......................................................
Take the bus ......................................................
Can you hear normal speech 
(if necessary with hearing aid)? .......................
Can you read (if necessary with glasses)? .....
Are you dependent on any of the following aids? 
Walking stick ................................................
Crutches ...........................................................




How many visits have you made during the past year   
due to your own health or illness: 
Put 0 if you have not had such contact 
To a general practitioner (GP)/emergency GP ........
To a psychologist or psychiatrist .................................
To an other medical specialist (not at a hospital) .......
To a hospital out-patient clinic .................................
Admitted to a hospital ....................................................
To a physiotherapist ......................................................
To a chiropractor .......................................................
To a acupuncturist .........................................................
To a dentist .....................................................................
To a chiropodist .........................................................
To an alternative practitioner (homoeopath, foot zone therapist, etc.)
To a healer, faith healer, clairvoyant ............................
Do you have home aid? 
Private ...........................................................
Municipal ..........................................................
Do you receive home nursing care? ...................
Are you pleased with the health care and home
assistance services in the municipality? 
Assigned family GP .................................
Home nursing care ......................................
Home assistance services ..........................
Do you feel confident that you will receive health 





Have you for any length of time in the last year used any of the 
following medicines or dietary supplements daily or almost daily? 
Indicate how many months you have used them. 








Heart medicines (not blood pressure) ...............
Insulin .......................................................................
Diabetes tablets  ......................................................
Drugs for hypothyroidism (Thyroxine) .............
Cortisone tablets .....................................................
Remedies for constipation .....................................
Dietary supplements: 
Iron tablets ...........................................................
Vitamin D supplements ...........................................
Other vitamin supplements ....................................
Calcium tablets or bone meal ............................
Cod liver oil or fish oil capsules ............................
Do you have close relatives who can give 
you help and support when you need it? .......




How many good friends do you have whom you  
can talk confidentially with and who give you 
help when you need it? ...............................................
Do not count people you live with, but do include 
other relatives! 
Do you feel you have enough good friends?
Do you feel that you belong to a community (group of people) 
who can depend on each other and who feel committed to each 
other (e.g. a political party, religious group, relatives, neighbours, 
work place, or organisation)? 
Strong sense of belonging ...................................
Some sense of belonging .........................................
Not sure ......................................................................






 No  
Yes With difficulty  No 
 No  Yes 
Number of times




 No  Yes 


















        FOOD HABITS           
     WELL BEING       
     MENSTRUATION       
       PREGNANCY        
        ESTROGEN           
How often do you normally take part in organised gatherings, 
e.g. sewing circles, sports clubs, political meetings, religious 
or other associations? 
Never, or just a few times a year ..........................
1-2 times a month ......................................................
Approximately once a week .....................................
More than once a week .............................................
How many meals a day do you normally eat      
(dinner and bread meals)? ...............................................
How many times a week do you eat warm dinner? ........
What kind of bread (bought or home-made) do you              
usually eat? 
Tick one or two boxes. 
The bread type is most similar to:
What kind of fat is normally used in cooking 






How much (in number of glasses, cups, potatoes or slices) do you   
usually eat/drink daily the following foodstuffs? 
Tick one box for each foodstuff. 
Milk of all types (glasses) ..................
Orange juice (glasses) ...........................
Potatoes ..................................................
Slices of bread in total (incl. crispbread)
Slices of bread with 
fish (e.g. mackerel in tomato sauce) 
cheese (e.g. Gouda/Norvegia) ...................
smoked cod caviare .......................
How many times per week do you normally 
eat the following foodstuffs? 
Tick for all foodstuffs listed. 
Yoghurt .........................................
Boiled or fried egg ...........................
Breakfast cereal/oatmeal, etc. .........
Dinner with   
unprocessed meat ........................
fatty fish (e.g. salmon/red-fish)
lean fish (e.g. cod) ....................
vegetables (fresh or cooked) .......
Carrots (fresh or cooked) ................
Cauliflower/cabbage/broccoli .........
Apples/pears ....................................
Oranges, mandarins, etc. ............
Your comments:       
How content do you generally feel with growing old? 
Good ........................................................................
Quite good ..................................................................
Up and down ..............................................................
Bad ...............................................................................
What is your view of the future?        
Bright ......................................................................
Not too bad .................................................................
Quite worried ..............................................................
Dark ..............................................................................
How old were you when you started  
menstruating? ................................................................
TO BE ANSWERED BY WOMEN ONLY  
How old were you when you stopped menstruating? 
How many children have you given birth to? ........
If you have given birth, fill in for each child the year of birth 
and approximately how many months you breastfed the child. 
If you have given birth to more than 6 children, note their birth 
year and number of months you breastfed at the space provided 
below for comments.   
Child  Year of birth: Number of months    
breastfed:  
Children
Have you during pregnancy    
had high blood pressure and/or             
proteinuria? .......................................................
If "Yes", during which pregnancy? 
High blood pressure ..................................
Proteinuria ..................................................
  First    Later   
Pregnancy      
 No  Yes 
Do you use, or have you ever used estrogen:              
Tablets or patches ...........................................
Cream or suppositories ...................................
If you use estrogen, what brand do you currently use?     
Now  Previously  Never
years 
years 
 Never   
 Less  
   than 1     




 Less    
 than 1  
None  
 White





  Coarse   
brown  
   Crisp   
  bread  
 Number  
Thank you for the help! Remember to mail the form today! 
Tromsø Health Survey 
